Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  10-Jan-2020A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical 
Trial to Evaluate the Safety and Efficacy of Letermovir (LET) 
Prophylaxis When Extended From 100 Days to 200 Days Post-
Transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) 
of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
PRODUCT: MK-8228 1
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3 randomized, double -blind, placebo- controlled clinical trial to 
evaluate the safety and efficacy of letermovir (LE T) proph ylaxis when extended from 
100days to 200 days post -transplant in cy tomegalovir us (CMV) seropositive recipients (R+) 
of an allogeneic hematopoietic stem cell transplant (HSCT)
Protocol Number: 040-02
Compound Number: MK-8228
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
EudraCT
IND2018- 001038
-17
104,706 (tablet); 118,361 (IV)
Approval Date: 10 January 2020 
  05DKLV
080V09
PRODUCT: MK-8228 2
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date 
  05DKLV
080V09
PRODUCT: MK-8228 3
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 02 10-JAN-2020 The primary  purpose of this protocol amendment is to limit enrollment of participants 
who have anti-thymocy te globulin as the onl y high-risk category  for CMV reactivation to 
20% of the total trial population.  This is t o ensure that the preponderance of evidence 
does not come from participants with anti -thymocy te globulin as the onl y high- risk 
category  for late CMV react ivation .
Amendment 01 23-AUG- 2019 The primary  purpose of this protocol amendment is to add the requirement that the 
intravenous (IV) formulation of letermovir (LET) supplied by  the Sponsor to sites as 
study  medication must be administered through a sterile 0.2 -micron or 0.22 -micron 
polyethersulfone (PES) in -line filter and using diethy lhexyl phthalate (DEHP) -free IV 
bags and infusion set materials.  This requirement i s being added to prevent the possible 
administration of product -related particulate matter.  The presence of visible product -
related particulate matter is an expected characteristic of new clinical supplies of IV 
formulation of LET.  This requirement is be ing implemented to allow for the release of 
new clinical supplies of IV LET, and as a precaution, it must be applied regardless of 
whether the clinical site considers its current clinical supply  to be impacted.  I n addition, 
the matching placebo to the IV formulation of LET must also be administered through a 
sterile 0.2 -micron or 0.22 -micron PES in -line filter and using DEHP -free IV bags and 
infusion set materials, in order to maintain the blind for IV study  medications.
Original Protocol 
(Version 00)03-DEC -2018 Original protocol 
  05DKLV
080V09
PRODUCT: MK-8228 4
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: [02]
Overall Rationale for the Amendments:
The primary  purpose of this protocol amendment is to limit enrollment of participants who have anti-thymocy te globulin as the only  
high-risk category  for CMV reactivation to  20% of the total trial population.  This is t o ensure that the preponderance of evidence 
does not come from participants with anti -thymocy te globulin as the onl y high- risk category  for late CMV reactivation .
Summary of Changes Table:
Section # and Name Description of Change Brief Rationale 
5.1 Inclusion Criteria Criterion #5 (“at high risk of CMV disease, 
defined as meeting one or more of the 
following criteria”); 
Subpart “f”:
Was: “receipt of anti -thymocy te globulin”
Now :“receipt of anti -thymocy te 
globulin ( Note: e nrollment of participants 
whose ONLY high -risk factor is the use of 
anti-thymocy te globulin will be restricted 
to 20% of all enrolled participants)”To ensure adequate representatio n of all other 
subgroups of participants that are at high risk of 
CMV infection.
Subpart “e”:
Was: “having T -cell– depleted grafts”
Now: “having ex -vivo T -cell–depleted 
grafts”To clarify  that this criterion should be restricted 
to participants with ex vivo T- cell depletion onl y.  
  05DKLV
080V09
PRODUCT: MK-8228 5
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Section # and Name Description of Change Brief Rationale 
6.1 Study  Intervention(s) 
AdministeredFootnote added to Table 1 (Study Therapy –
Oral [Tablet ] Formulation ) and Table 2 
(Study Therapy – Intravenous Formulation ) 
within the column header for “IMP/NIMP”:
“The classification of Investigational 
Medicinal Product (IMP) and Non -
Investigational Medicinal Product (NIMP) 
in this table is based on guidance issued 
by the European Commission and applies 
to countr ies in the European Economic 
Area (EEA). Country  differences with 
respect to the definition/classification of 
IMP/NIMP may  exist. I n these 
circumstances, local legislation is 
followed.”To align with updated template text, allowing for 
country  differences with respect to 
definition/classification of IMP/NI MP.
8.2.1CMV DNA PCR Testing Language added requiring sites in Japan to 
conduct pp65 antigen testing locall y at the 
CMV infection visit along with the 
confirmatory  CMV -DNA PCR test sample 
being sent to t he central laboratory .Most sites in Japan use pp65 antigen testing to 
drive decisions to initiate PET.  Section modified 
to specify  that such sites are required to obtain a 
repeat pp65 antigen test locally  immediatel y prior 
to initiating anti- CMV therap y.   
  05DKLV
080V09
PRODUCT: MK-8228 6
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Section # and Name Description of Change Brief Rationale 
10.2 Appendix 2 : Clinical 
Laboratory  TestsTable of laboratory  tests [Table 9] 
restructured to identify  those tests that must 
be performed b y the central laboratory  from 
those that may  be performed by  the central or 
the local laboratory . 
Table renamed (from “Laboratory  
Assessments Performed by  the Central 
Laboratory ” to “Laboratory  Assessments”)Modified for improved clarity .  
Global Minor grammatical, t ypographical, and 
syntactical modifications made for improved 
accuracy  and clarity , and to ensure 
consistency  of language across the protocol. 
  05DKLV
080V09
PRODUCT: MK-8228 7
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table of Contents
DOCUMENT HISTORY ........................................................................................................3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ................................
............................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 18
1.3 Schedule of Activities (SoA) ................................................................................ 19
2 INTRODUCTION .......................................................................................................... 24
2.1 Study Rationale ....................................................................................................24
2.2 Background .......................................................................................................... 25
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 25
2.2.2 Preclinical and Completed Clinical Studies ................................................. 25
2.2.3 Ongoing Clinical Studies ............................................................................. 26
2.3 Benefit/Risk Assessment ...................................................................................... 26
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 26
4 STUDY DESIGN ............................................................................................................ 29
4.1 Overall Design ......................................................................................................29
4.2 Scientific Rationale for Study Design ................................................................ .30
4.2.1 Rationale for Endpoints ............................................................................... 31
4.2.1.1 Efficacy  Endpoints ............................................................................. 31
4.2.1.2 Safety  Endpoints ................................................................................ 32
4.2.1.3 Other Endpoints ................................................................................. 33
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 34
4.3 Justification for Dose ........................................................................................... 34
4.4 Beginning and End of Study Definition ............................................................. 34
4.4.1 Clinical Criteria for Early Study Termination ............................................. 34
5 STUDY POPULATION ................................................................................................ 35
5.1 Inclusion Criteria ................................................................................................ .35
5.2 Exclusion Criteria ................................................................................................ 36
5.3 Lifestyle Considerations ...................................................................................... 39
5.3.1 Meals and Dietary Restrictions ....................................................................39
5.4 Screen Failures .....................................................................................................39
5.5 Participant Replacement Strategy ......................................................................39
6 STUDY INTERVENTION ............................................................................................ 40
6.1 Study Intervention(s) Administered ...................................................................40
6.2 Preparation/Handling/Storage/Accountability ................................................. 42 
  05DKLV
080V09
PRODUCT: MK-8228 8
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
6.2.1 Dose Preparation .......................................................................................... 42
6.2.2 Handling, Storage, and Accountability ........................................................ 42
6.2.3 Participant -level Study  Medication Accountabilit y.....................................43
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 43
6.3.1 Intervention Assignment.............................................................................. 43
6.3.2 Stratification ................................................................................................ .43
6.3.3 Blinding........................................................................................................43
6.4 Study Intervention Compliance .......................................................................... 44
6.5 Concomitant Therapy .......................................................................................... 44
6.5.1 Allowed Medications/Therapies to be Administered with Clinical 
and/or Drug Level Monitoring when Coadministered with Study  
Therap y........................................................................................................44
6.5.2 Prohibited Medications ................................................................................ 46
6.5.2.1 Medications Prohibited with Study Medication ................................ 47
6.5.2.2 Additional Medications Prohibited When Study  Medication is 
Co-administered with CsA ................................................................ .48
6.5.3 Rescue Medications and Supportive Care ................................................... 49
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 49
6.7 Intervention After the End of the Study ............................................................ 49
6.8 Clinical Supplies Disclosure ................................................................................ 49
6.9 Standard Policies ..................................................................................................50
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL ............................................................................................................ 50
7.1 Discontinuation of Study Intervention ............................................................... 50
7.2 Participant Withdrawal From the Study ........................................................... 52
7.3 Lost to Follow -up................................................................................................ .52
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 53
8.1 Administrative and General Procedures ........................................................... 54
8.1.1 Informed Consent ......................................................................................... 54
8.1.1.1 General Informed Consent ................................................................ .54
8.1.2 Inclusion/Exclusion Criteria ........................................................................54
8.1.3 Participant Identification Card .....................................................................55
8.1.4 Medical History ........................................................................................... 55
8.1.5 Prior and Concomitant Medications Review ............................................... 55
8.1.5.1 Prior Medications ............................................................................... 55
8.1.5.2 Concomitant Medications ..................................................................55
8.1.6 Assignment of Screening Number ............................................................... 55
8.1.7 Assignment of Treatment/Randomization Number .....................................56
8.1.8 Study  Intervention Administration .............................................................. 56 
  05DKLV
080V09
PRODUCT: MK-8228 9
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.1.8.1 Timing of Dose Administration ......................................................... 56
8.1.9 Discontinuation and Withdrawal ................................................................ .57
8.1.10 Participant Blinding/Unblinding ..................................................................57
8.1.11 Domiciling ...................................................................................................57
8.1.12 Calibration of Equipment ............................................................................. 58
8.2 Efficacy Assessments ........................................................................................... 58
8.2.1 CMV DNA PCR Testing ............................................................................. 58
8.2.2 CMV DNA Resistance Analy sis..................................................................59
8.3 Safety Assessments ............................................................................................... 59
8.3.1 Physical Examinations ................................................................................. 59
8.3.2 Vital Signs....................................................................................................60
8.3.3 Electrocardiograms ...................................................................................... 60
8.3.4 Child -Pugh Score ......................................................................................... 60
8.3.5 Clinical Safety  Laboratory  Assessments ..................................................... 60
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 61
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 61
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Sa fety Events ......63
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...63
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 64
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 64
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 64
8.4.7 Events of Clinical I nterest (ECI s)................................................................ 64
8.5 Treatment of Overdose ........................................................................................ 65
8.6 Pharmacokinetics................................................................................................ .65
8.7 Pharmacodynamics .............................................................................................. 65
8.8 Future Biomedical Research Sample Collection ............................................... 65
8.9 Planned Genetic Analysis Sample Collection .................................................... 65
8.10 Biomarkers ........................................................................................................... 65
8.11 Health Outcomes Assessment ............................................................................. 66
8.12 Visit Requirements ............................................................................................... 66
8.12.1 Screening......................................................................................................66
8.12.2 Treatment Period .......................................................................................... 66
8.12.2.1 Day 1 Visit ......................................................................................... 67
8.12.2.2 Study  Medication Administration ...................................................... 67
8.12.3 Optional Nurse Visit and Telephone Visit (Weeks 3 2 and 36 Only ).......... 68 
  05DKLV
080V09
PRODUCT: MK-8228 10
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.12.4 Follow -up Period/Visits ............................................................................... 68
8.12.5 Discontinued Participants Continuing to be Monitored in the Study .......... 68
8.12.5.1 Discontinuation of Study Medication due to CMV I nfection ............ 68
8.12.5.2 Discontinuation for Reasons Other Than CMV Infection ................. 69
8.12.6 Survival Status ............................................................................................. 69
9 STATISTICAL ANALYSIS PLAN ............................................................................. 69
9.1 Statistical Analysis Plan Summary.....................................................................69
9.2 Responsibility for Analyses/In -house Blinding ................................................. 71
9.3 Hypotheses/Estimation ........................................................................................ 71
9.4 Analysis Endpoints ............................................................................................... 71
9.4.1 Efficacy /Immunogenicity /Pharmacokinetics Endpoints .............................. 71
9.4.1.1 Efficacy  Endpoints ............................................................................. 71
9.4.2 Safety  Endpoints .......................................................................................... 73
9.4.3 Exploratory  Endpoints ................................................................................. 73
9.5 Analysis Populations ............................................................................................ 74
9.5.1 Efficacy  Anal ysis Populations .....................................................................74
9.5.2 Safety Anal ysis Populations ........................................................................74
9.6 Statistical Methods ............................................................................................... 75
9.6.1 Statistical Methods for Efficacy  Anal yses................................................... 75
9.6.2 Statistical Methods for Safety Anal yses...................................................... 79
9.7 Interim Analyses ..................................................................................................80
9.8 Multiplicity ........................................................................................................... 81
9.9 Sample Size and Power Calculations ................................................................ .81
9.9.1 Sample Size and Power for Efficacy  Analy sis............................................ 81
9.9.2 Sample Size and Power for Safet y Anal ysis................................................ 82
9.10 Subgroup Analyses ............................................................................................... 83
9.11 Compliance (Medication Adherence) ................................................................ .84
9.12 Extent of Exposure ............................................................................................... 84
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................85
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........85
10.1.1 Code of Conduct for Clinical Trials ............................................................. 85
10.1.2 Financial Disclosure ..................................................................................... 87
10.1.3 Data Protection ............................................................................................. 87
10.1.3.1 Confidentiality  of Data ......................................................................88
10.1.3.2 Confi dentiality  of Participant Records ............................................... 88
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 88
10.1.4 Committees Structure ................................................................................... 88 
  05DKLV
080V09
PRODUCT: MK-8228 11
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.1.4.1 Scientific Advisory  Committee .......................................................... 88
10.1.4.2 Executive Oversight Committee ........................................................ 88
10.1.4.3 External Data Monitoring Committee ............................................... 89
10.1.4.4 Clinical Adjudication Committee (CAC) .......................................... 89
10.1.5 Publication Policy ........................................................................................ 89
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...90
10.1.7 Compliance with Law, Audit, and Debarmen ............................................. 90
10.1.8 Data Qualit y Assurance ............................................................................... 91
10.1.9 Source Documents ....................................................................................... 91
10.1.10 Study  and Site Closure ................................................................................. 92
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 93
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 97
10.3.1 Definition of AE .......................................................................................... 97
10.3.2 Definition of SAE ........................................................................................ 98
10.3.3 Additional Events Reported .........................................................................99
10.3.4 Recording AE and SAE ............................................................................... 99
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the
Sponsor ......................................................................................................103
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ......................................... 104
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ...................... 105
10.5.1 Definitions ..................................................................................................105
10.5.2 Contraception Requirements ......................................................................105
10.5.3 Pregnancy  Testing ...................................................................................... 107
10.6 Appendix 6: Country -specific Requirements .................................................. 108
10.7 Appendix 7 Definition of CMV Disease in Hematopoietic Stem Cell 
Transplant (HSCT) Recipients .........................................................................109
10.8 Appendix 8 Child -Pugh Classification for Severity of Liver Disease ............ 112
10.9 Appendix 9: Abbreviations ............................................................................... 113
11 REFERENCES............................................................................................................. 115 
  05DKLV
080V09
PRODUCT: MK-8228 12
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
LIST OF TABLES
Table 1Study Therapy  –Oral (Tablet) Formulation ..................................................... 41
Table 2Study Therapy  –Intravenous Formulation ....................................................... 41
Table 3Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safet y Events .................................................................................. 62
Table 4Summary  of Approaches to Handle Missing Values ........................................75
Table 5Analy sis Strategy  for Key  Efficacy  Variables .................................................. 78
Table 6Analy sis Strategy for Safety  Parameters ........................................................... 80
Table 7Power(%) Under Various Assumptions (With 144 Participants 
Randomized in 200 -day Arm and 72 in 100 -day Arm) ....................................82
Table 8Estimate of Incidence of AEs and 95% Upper Confidence Bound Based on 
Hypothetical Numbers of Participants with AEs .............................................. 83
Table 9Laboratory  Assessments .................................................................................... 94
Table 10Approximate Blood/Tissue Volumes Drawn/Collected b y Study Visit and 
by Sample Ty pes............................................................................................... 96
Table 11Contraceptive Methods ................................................................................... 106 
  05DKLV
080V09
PRODUCT: MK-8228 13
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
LIST OF FIGURES
Figure 1Study  Design .....................................................................................................18 
  05DKLV
080V09
PRODUCT: MK-8228 14
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3 randomized, double -blind, placebo- controlled clinical trial to 
evaluate the safet y and efficacy  of letermovir (LET) prophy laxis when extended from 100 
days to 200 day s post -transplant in cy tomegalovirus (CMV) seropositive recipients (R+) of 
an allogeneic hematopoietic stem cell transplant (HSCT)
Short Title: Extension of LET from Day  100 to Day 200 post -transplant for the prevention 
of CMV infection in HSCT participants
Acronym: Not Applicable
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with the objectives in the Objectives and Endpoints table.
InCMV seropositive recipients (R+) of an allogeneic HSCT who have received L ET 
prophy laxis through Day 100 post -transplant and are at high risk for CMV infection and/or 
disease after ~100 days post -transplant :
Primary  Objectives Primary  Endpoints
Objective: To evaluate the efficacy  of 
letermovir (LET) versus placebo when LET 
prophy laxis is extended from 100 to 
200days post -transplant, as measured by  
the proportion of participants with clinically 
significant CMV infection from Week 14 
(~100 days) post -transp lant through 
Week 28 (~200 days) post -transplant
Hypothesis (H1): LET is superior to placebo 
in the prevention of clinically  significant 
CMV infection when LET prophy laxis is 
extended from 100 to 200 days 
post-transplantClinically  significant CMV infectio n 
(CS-CMVi, defined as initiation of 
pre-emptive therap y [PET] for documented 
CMV viremia and/or CMV end -organ 
disease) 
  05DKLV
080V09
PRODUCT: MK-8228 15
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Secondary  Objectives Secondary  Endpoints
To evaluate the safet y and tolerability  of 
LET versus placebo when L ET prophy laxis 
is extende d from 100 to 200 days 
post-transplant based on the proportion of 
participants with adverse events from 
Week 14 post -transplant through Week 28 
post-transplant.AEs
Study  drug discontinuations due to AEs
To evaluate the efficacy  of L ET versus 
placebo when LET prophylaxis is extended 
from 100 to 200 days post -transplant, as 
measured b y the following: 
-Proportion of participants with clinically  
significant CMV infection from Week 14 
post-transplant through Week 38 and from 
Week 14 post -transplant through W eek48 
post-transplant
-Time to onset of clinically  significant 
CMV infection from Week 14 
post-transplant through Week 28 
post-transplant, and from Week 14 
post-transplant through Week 48 
post-transplant
-Proportion of participants with pre -
emptive therap y (PET) for CMV viremia 
from Week 14 post -transplant through 
Week 28 post -transplant, and from Week 14 
post-transplant through Week 48 
post-transplant
-Proportion of participants with all -cause 
mortality  from Week 14 post- transplant 
through Week 28 post -transplant, and from 
Week 14 post -transplant through Week 48 
post-transplant
-Time to all -cause mortality  from Week 14 
post-transplant through Week 28 
post-transplant, and from Week 14 
post-transplant through Week 48 
post-transplantClinically  signif icant CMV infection
Initiation of anti- CMV PET for documented 
CMV viremia
All-cause mortalit y 
  05DKLV
080V09
PRODUCT: MK-8228 16
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Overall Desig n:
Study  Phase Phase 3
Primary  Purpose Prevention
Indication Prevention of clinicall y significant CMV infection in adult
allogeneic HSCT recipient
Population CMV seropositive recipients post -transplant who have 
received LET proph ylaxis through Day  100 
post-transplant and are at high risk for CMV infection 
and/or disease after ~100 days post-transplant
Study  Type Interventional
Interventi on Model Parallel
Amulti- sitestudy
Type of Control Placebo
Study  Blinding Double -blind
Masking Investigator
Participant
Care Provider
Outcomes Assessor
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 36months from the time the first 
participant signs the informed consent until the last 
participant’s last study -related telephone call or visit.
Number of Participant s:
Approximately  216 participants will be randomized/enrolled. 
  05DKLV
080V09
PRODUCT: MK-8228 17
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Intervention Groups and Duration :
Intervention 
Group sDrugDose
StrengthDose 
FrequencyRoute of 
Administration Use
LET
LET (for 
participants on 
CsA)240 mg Once daily Oralaor IVb cExperimental
LET (for 
participants not 
on CsA)480 mg 
Once daily Oralaor IVb cExperimental
PLACEBO
Placebo for LETNot 
ApplicableOnce daily Oralaor IVb c Placebo 
comparator
Duration :Interventions will be given from  post-transplant Week 14 to 
post-transplant Week 28
LET = letermovir; CsA = Cyclosporin A ; IV = intravenous
a:The number of placebo tablets will mimic the LET dosing scheme in an effort to maintain the 
blind (ie, 1 matching placebo tablet if on CsA to mimic one 240 -mg tablet ; 1 or 2 matching 
placebo tablets if not on CsA to mimic one 480 -mg tablet or two 240 -mg tablets, respectively).
b:LET IV formulation dosing volume is 250 mL and duration of infusion will be approximately 
60minutes. LET IV will be provided as a sterile liquid concentrate for dilution (20 mg/mL), one 
vial to be used for the 240 -mgdose and two vials for the 480 -mg dose. Locally supplied sterile 
IV dextrose or saline diluent will be used as the placebo to LET IV as prepared by the site 
unblinded pharmacist.
c:The IV formulation should be switched to oral study therapy (ie, at the next planned dose) as 
soon as participants are able to swallow and/or the condition necessitating the use of the IV 
formulation resolves.
Total 
Number2intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  36weeks
from the time the participant signs the Informed Consent F orm (ICF) 
through the final contac t.  After a screening phase of up to 2weeks , each 
participant will be receiving assigned intervention for approximately  
14week s.  After the end of treatment each participant will be followed for 
20weeks . 
  05DKLV
080V09
PRODUCT: MK-8228 18
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee Yes
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 9.
1.2 Schema
The study  design is depicted in Figure 1.
Figure 1Study  Design
 
  05DKLV
080V09
PRODUCT: MK-8228 19
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
1.3 Schedule of Activities (SoA)
Study PeriodTreat ment Period
(14weeks of study therapy;
Weeks 14-28 or ~100 -200days 
post-transplant)Follow -upCMV i 
or 
Early 
D/C a, bNotes
Visit No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Post-transplant Week SCR c14d
(D1)16 18 20 22 24 2628 30 32e34 36e38 40 44 48D1 = Day 1 of study = day of 
randomization which should 
occur at14 weeks ( 100days)
±1week post -transplant
Visit Window -14days ±3 days ±7 days ±14 days
Admin istrative Procedures
Informed consent ×
Participant ID card ×Will be updated once 
randomized
Inclusion /exclusion × ×
Medical history × ×
Prior/c onmeds review × × × × × × × × × × × × × × ×
HSCT details review ×Collect conditioning regimen;
date and type of transplant;
source of stem cells ;type of 
graft manipulation ;presence of 
GVHD; and GVHD prophylaxis 
regimen (if any) 
Treatment allocation ×
Study therapy dispensing × × × × × × ×Contact IRT at all dispensing 
visits (See Section 8.1.8)
Study medication administration × × × × × × × × 
  05DKLV
080V09
PRODUCT: MK-8228 20
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Study PeriodTreat ment Period
(14weeks of study therapy;
Weeks 14-28 or ~100 -200days 
post-transplant)Follow -upCMV i 
or 
Early 
D/C a, bNotes
Visit No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Post-transplant Week SCR c14d
(D1)16 18 20 22 24 2628 30 32e34 36e38 40 44 48D1 = Day 1 of study = day of 
randomization which should 
occur at14 weeks ( 100days)
±1week post -transplant
Visit Window -14days ±3 days ±7 days ±14 days
Study Medication Diary review × × × × × × × ×Participant will be trained on 
the use of Study Medication 
Diary on Day 1.  Study 
Medication Diary will be 
collected/ redistributed at each 
visit after Day 1.
Clinical Procedures/
Assess ments
Full Physical Examination × ×
Targeted physical e xamination × × × × × × × × × × × × × ×Performed only when clinically 
indicated
Weight × ×××××××× ×
Height ×
Vital signs × × × × × × × × × × × × × × × ×HR, BP, respiratory rate, body 
temperature
12-lead ECG ×Read locally. Values collected 
within 1 month prior to 
screening may be used for 
Visit 1.
Semi -recumbent position.
Child -Pugh score × × × × × × × × × ×Only when participant is on 
study medication. Laboratory 
testing for Child- Pugh scoring 
to be done locally after Visit 1
Confirm birth control (WOCBP 
only)× × × × × × × × × × × ×Acceptable methods of 
contraception to be used f rom 
the time of consent through 
28days after the last dose of 
study therapy . 
  05DKLV
080V09
PRODUCT: MK-8228 21
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Study PeriodTreat ment Period
(14weeks of study therapy;
Weeks 14-28 or ~100 -200days 
post-transplant)Follow -upCMV i 
or 
Early 
D/C a, bNotes
Visit No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Post-transplant Week SCR c14d
(D1)16 18 20 22 24 2628 30 32e34 36e38 40 44 48D1 = Day 1 of study = day of 
randomization which should 
occur at14 weeks ( 100days)
±1week post -transplant
Visit Window -14days ±3 days ±7 days ±14 days
AE monitoring × × × × × × × × × × × × × × × ×All AEs will be reported 
through 14 days after last dose 
of study medication .  
Thereafter, only drug -related 
SAEs or SAEs leading to death 
to reported until study 
completion (see Section 8.4) 
Chemistry/ hematology × × × × × × × × × × ×Refer to Section 8.3.4 for 
further details 
Coagulation PT/INR × × × × × × × × × ×Performed centrally at 
Screening visit; locally 
thereafter
Urinalysis × × ×Refer to Section 8.3.4 for 
further details regarding the 
laboratory safety tests
Serum (β -hCG)
(WOCBP only)×
Urine pregnancy (WOCBP only) × × × × ×Performed locally; serum 
pregnancy test must be 
performed to confirm a positive 
urine test result. 
  05DKLV
080V09
PRODUCT: MK-8228 22
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Study PeriodTreat ment Period
(14weeks of study therapy;
Weeks 14-28 or ~100 -200days 
post-transplant)Follow -upCMV i 
or 
Early 
D/C a, bNotes
Visit No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Post-transplant Week SCR c14d
(D1)16 18 20 22 24 2628 30 32e34 36e38 40 44 48D1 = Day 1 of study = day of 
randomization which should 
occur at14 weeks ( 100days)
±1week post -transplant
Visit Window -14days ±3 days ±7 days ±14 days
HIV, Hepatitis B and C screen ×Documented neg HIV results at 
any time prior to screening 
acceptable. HBV/HCV to be done
if not documented within the 
previous 6 months . If hepatitis C 
virus antibody is positive, RNA 
PCR results should be provided.
CMV Procedures/ Assessments
CMV DNA PCR × × × × × × × × × × × × × × × × × ×
CMV disease assessment × × × × × × × × × × × × × × × × × ×All clinical signs and symptoms 
of CMV disease and review of 
relevant laboratory parameters
QuantiFERON -CMV assay × × × ×
CMV DNA sequence analysis ×fTo be performed ONLY in 
participant s with clinically 
significant CMV infection. 
Repeat samples should be 
collected at the next scheduled 
visit after the CMV Infection 
Visit.
Health Outcome Assessments × × × × × × × × × × × × × × × × ×Collect re-
hospitalizations, all -cause 
mortality, intravenous 
medications, select OIs, GVHD 
  05DKLV
080V09
PRODUCT: MK-8228 23
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
β-hCG = β -Hum an Chorionic Gonadotropin; CMV = cytomegalovirus; DNA = deoxyribonucleic acid; D = day ; FU = follow -up; GVHD = graft -versus -host disease ; HIV = human 
immunodeficiency virus ; HSCT = hematopoietic stem cell transplant; IRT=interactive response technology ;IV = intravenous ;LET = letermovir ; OI = opportunistic infection (s); 
PCR = polymerase chain reaction ; PET = pre -emptive therapy; PT/INR =prothrombin time / international normalized ratio ;SCR = screening ; TP= Transplant; WOCBP = woman 
of childbearing potential.
a. This visit will be a CMV Infection Visit for all participants who meet the endpoint of CS -CMVi (defined as the occurrence of CMV disease or the initiation of PET) 
through Week 48 post -transplant.  During the treatment period, LET must be discontinued at this visit (if the participant is still on LET).  All procedures at the visit 
indicated in the SoA should be completed immediately prior to initiating PET for CMV infection or treatment for CMV disease at this visit (ie, on the day anti -CMV 
therapy is initiated).  Most importantly, a plasma sample for CMV PCR testing at the central laboratory should be collected at this visit.
b. The visit will be an Early Study Discontinuation Visit for those participants who are prematurely discontinued from the study (not study medication alone) through 
Week 48 post-transplant. 
c.Screening should begin after obtaining documented consent and must begin up to 14 days prior to the planned randomization date .The day of randomization (Day 1) will 
beapproximately 14 weeks (100 days) ±1week post -transplant.  Participants will have plasma samples tested for CMV viremia using the CMV DNA PCR assay by the 
central laboratory. 
d.Day 1 of the study is the day of randomization, and will occur 14 weeks (100 days) ±1 week post-transplant .  On Day 1 , eligibility for enrollment into the study willbe 
confirmed.  At that time, participants should have no documented quantifiable CMV viremia, as confirmed by CMV DNA PCR assay at the central laboratory in a 
plasma sample collected within 14 days prior to randomization. Creatinine clearance and liver function test results should also be available within 14 days prior to 
randomization .It is required that eligible participants have no more than 14 days of LET interruption prior to randomization . 
Study thera py must begin on Day 1 .Day 1 procedures/assessments must be performed prior to the first dose of study therapy.
e.A visiting nurse service may be utilized (if locally available and approved for use) for these visits in coordination with an investigator CMV assessment by phone.  If a 
visiting nurse service is utilized, the investigator phone call should occur on the same day as the nurse visit, or as soon a s possible.  Refer to the nursing manual for 
additional details.
f.For participants with clinically signif icant CMV infection, asample for CMV DNA sequence analysis for LET resistance should be collected at the CMVi visit anda 
second, confirmatory sample should be collected at the next scheduled visit following the CMVi visit. 
  05DKLV
080V09
PRODUCT: MK-8228 24
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
2 INTRODUCTION
2.1 Study Rationale
Individuals who receive stem -cell or organ transplantation undergo immunosuppressive 
treatments that put them at high risk for select opportunistic infections.  Cy tomegalovirus 
(CMV) isthe most common clinically  significant viral infection after transplant , causing
substantial morbidity  and mortality in transplant recipients due to direct ( eg,pneumonia, 
hepatitis, retinitis, enc ephalitis) [Boeckh, M. and Geballe, A. P. 2011] [L jungman, P., et al 
2002] [Boeckh, M. 2011] , and indirect (eg,increased risk of select opportunistic bacterial 
and invasive fungal infections, graf t-versus -host disease [GVHD] , delay ed engraftment or 
graft failure/rejection, increased overall mortality )effects [Craddock, C., et al 2001] [Miller, 
W., et al 1986] [Özdemir, E., et al 2007] [Martino, R., et al 2001] [Söderberg, C., et al 1993] 
[Larsson, K., et al 2004] [Marty, F. M. and Boeckh, M. 2011] [Ariza -Heredia, E. J., et al 
2014] .  Hematopoietic stem cell transplant (HSCT) r ecipients are at highest risk for CMV 
infection and/or disease within the first 100days (approximately  14weeks) after 
transplantation.  
Letermovir (LET, also known as MK -8228, AI C246, AI C001 ) is a potent inhibitor of the 
CMV viral terminase and is appro ved for proph ylaxis of CMV infection and/or disease in 
adult CMV seropositive recipients ( R+)of an allogeneic HSCT .  LET was overall 
well-tolerated and efficacious in a pivotal Phase 3 study  (P001) for the prophy laxis of CMV
infection or disease in adult CMV recipients R+of an allogeneic HSCT [Marty, F. M., et al 
2017] .  In this randomized, placebo- controlled P hase 3 study , LET proph ylaxis when started 
within 28 days post-transpla ntand continued until Week 14 (~100 days) post-transplant
effectivel y prevented clinical lysignificant CMV viremia through Week 24 post-transplant .  
At Week 14post-transplant (end of stud y treatment) , 19.1% participants on LET developed 
clinically  signif icant CMV infection compared to 50% participants on placebo
(non-completer=failure analysis, NC=F) .  After stopping LET at Week 14post-transplant , 
there was an increase in clinically significant CMV infection through Week 24 
post-transplant with 37.5% of participants on LET develop ingclinically  significant CMV 
infection compared to 60.6% participants on placebo ( p<0.0001) at Week 24 post-transplant
(NC=F) .  The all -cause mortality  atWeeks 24 and 48 after transplantation was lower in the 
LET group (10.2% and 20.9%, respectively ) than the placebo group (15.9% and 25.5%, 
respectivel y).  LET was well -tolerated with no evidence of m yelotoxicity; participants who 
received LET had a similar time to engraftment (defined as the process of transplanted st em 
cells reproducing new cells) compared to those who received placebo. 
The risk for CMV infection in HSCT recipient sisreduced after the first 100 days 
post-transplant as the immune sy stem reconstitutes.  However, there are certain HSCT 
population s who remain at high risk for CMV infection beyond 100 days post-transplant due 
to delay ed immune reconstitution ,ongoing immunosuppression as a result of treatment for
GVHD, or onset of new GVHD when immunosuppression is tapered .  In a post-hoc anal ysis 
of results from P001 , factors predictive of the development of clinically  significant CMV 
infection between Weeks 1 4 and 24 post-transplant include high risk stratum at baseline 
(based on donor relatedness and degree of matching, stem -cell source, and T-c ell depleted  
  05DKLV
080V09
PRODUCT: MK-8228 25
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
grafts), occurrence of GVHD, and steroid use following randomization.   CMV infection 
occurring a fter ~ 100days post-transplant is associated with morbidity  and is an independent 
predictor of mortality  [Erard, V, Guthrie, K. A. 2015] .  However, t he benefit of prolonged 
prophy laxis for prevention of CMV infection/disease after 100 days post-transplant in HSCT 
recipients remains unclear . The standard ofcare for prevention of CMV infection/disease 
after 100days post-transplant remains p re-emptive therap y (PET), which is defined as the 
practice of active surveillance for viral replicatio nwith antiviral treatment started only  when 
CMV viremia is detected [L jungman, P., et al 2002] . In a randomized ,double -blind trial of 
CMV prophy laxis with valganciclovir ( VGCV ) compared to 
placebo/ PET between ~3 -6 
months post -HSCT , CMV viremia was reduced in the VG CV group compared to placebo 
(11% vs 3 6% respectively , p<0.001) , but there was no difference in survival between the two 
arms [Boeckh, M., et al 2015] . 
The objective of this study  is to evaluate the occurrence of clinicall y significant CMV 
infection when LET prophy laxis is extended from Day 100 to Day  200post-transplant in 
CMV R+ recipients of an allogeneic HSCT who have received LET prophylaxis through 
Day 100 post -transplant and are at high risk for CMV infection and/or disease after
~100 days post-transplant.  The data from this study may guide the clinical management of 
CMV in allogeneic HSCT recipients who continue to beat high risk of CMV infection after 
~100 dayspost-transp lant.  
2.2 Background
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background 
information on LET.
2.2.1 Pharmaceutical and Therapeutic Background
LET is a novel inhibitor of the CMV viral enzyme DNA terminase (UL56/UL 89/UL51 ), an 
enzy me that play s an important role in the cleavage of newl y synthesized concatenated CMV 
DNA into individual unit-length viral genomes that are subsequently  inserted into CMV 
procapsids to generate infectious CMV virions [Goldner, T., et al 2011] .LET has 
demonstrated potent, selective, and reversible inhibition of CMV activity  in preclinica l 
studies in vitro and efficacy against the virus in vivo [Lischka, P., et al 2010] [Goldner, T., et 
al 2011] .
LET is currentl y availab le commercially  as oral tablet formulations andan intravenous 
formulation.  Participants in this study  will either receive the currently  marketed oral adult 
tablets (240 -mgor 480 -mg strength) or marketed intravenous formulation or placebo.
2.2.2 Preclinical and Completed Clinical Studies
Details of preclinical studies and completed clinical studies conducted with L ET can be 
found in the accompan ying IB. 
  05DKLV
080V09
PRODUCT: MK-8228 26
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
2.2.3 Ongoing Clinical Studies
One clinical stud y (P0 02) with L ET is currentl y ongoing .  It is aPhase 3randomized, 
multi- site, double -blind active comparator trial to evaluate the efficacy  and safet y of LET 
versus VGCV in adult kidney  transplant recipients.  Adult CMV donor seropositive 
(D+)/recipient seronegative ( R-)kidney  transplant recipients are being enrolled to receive 
either LET or VCVG starting within 7 dayspost-transplant and continuing through Week 28 
post-transplant .  Efficacy will be measured b y the proportion of participants with adjudic ated 
CMV disease through Week 52 post -transplant .  Safet y and tolerability in kidney transplant 
recipients will also be evaluated.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safet y and effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may be found in the accompan ying IB and ICF documents.
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with the objectives in the Objectives and Endpoints table.
InCMV seropositive recipients (R+) of an allogeneic HSCT who have received L ET 
prophylaxis through Day 100 post -transplant and are at high risk for CMV infection and/or 
disease after ~100 days post -transplant :
Objectives Endpoints
Primary
Objective: To eva luate the efficacy  of
letermovir (LET) versus placebo when 
LET proph ylaxis is extended from 100 
to 200 days post -transplant, as 
measured b y the proportion of 
participants with clinically significant 
CMV infection from Week 14 
(~100 days)post-transplant through
Week 28(~200 days)post-transplant
Hypothesis (H1): LET is superior to 
placebo in the prevention of clinically  
significant CMV infection when LET 
prophy laxis is extended from 100 to 
200days post -transplantClinically  significant CMV 
infection (CS -CMVi, defined as 
initiation of pre-emptive therap y 
[PET] for documented CMV 
viremia and/or CMV end -organ 
disease) 
  05DKLV
080V09
PRODUCT: MK-8228 27
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Objectives Endpoints
Secondary
To evaluate the safet y and tolerability  
of LET versus placebo when LET 
prophy laxis is extended from 100 to 
200days post -transplant based on the 
proportion of participants with adverse 
events from Week 14 post- transplant 
through Week 28 post -transplant.AEs
Study  drug discontinuations due 
to AEs
To evaluate the efficacy  of L ET versus 
placebo when LET prophylaxis is 
extended from 100 to 200 days 
post-transplant, as measured b y the 
following: 
Proportion of participants with 
clinically  significant CMV infection
from Week 14 post -transplant through 
Week 38 and from Week 14 
post-transplant through Week 48 
post-transplant
Time to onset of clinically significant 
CMV infection from Week 14 
post-trans plant through Week 28 
post-transplant, and from Week 14 
post-transplant through Week 48 
post-transplant
Proportion of participants with pre -
emptive therap y (PET)for CMV 
viremia from Week 14 post- transplant
through Week 28 post -transplant, and 
from Week 14post-transplant through 
Week 48 post -transplant
Proportion of participants with all-
cause mortalit yfrom Week 14 
post-transplant through Week 28 
post-transplant, and from Week 14 
post-transplant through Week 48 
post-transplantClinically  significant CMV 
infection
Initiation of anti -CMV PET for 
documented CMV viremia
All-cause mortalit y 
  05DKLV
080V09
PRODUCT: MK-8228 28
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Objectives Endpoints
Time to all-cause mortality from 
Week 14 post -transplant through 
Week 28 post -transplant, and from 
Week 14 post -transplant through 
Week 48 post -transplant
Exploratory
To evaluate the efficacy  of L ET versus 
placebo when LET prophylaxis is 
extended from 100 to 200 days 
post-transplant, as measured b y the 
following:
Proportion of participants with CMV 
end-organ disease from Week 14 
post-transplant through Week 28 
post-transpl ant, and from Week 14 
post-transplant through Week 48 
post-transplant
Proportion of participants with 
documented CMV viremia from 
Week 14 post -transplant through 
Week 28 post -transplant, and from 
Week 14 post -transplant through 
Week 48 post -transplantCMV end-organ disease
Documented CMV viremia
≥300 copies/mL
To evaluate health outcomes in L ET 
versus placebo from Week 14 
post-transplant through Week 28 
post-transplant, and from Week 14 
post-transplant through Week 48 
post-transplantRecurrent episodes of CMV 
infection
Select o pportunistic infections 
other than CMV infection
Graft-versus- host disease 
(GVHD)
All re-hospitalizations and re -
hospitalizations for CMV 
infection/disease
Intravenous medications other 
than LET 
  05DKLV
080V09
PRODUCT: MK-8228 29
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Objectives Endpoints
To evaluate the antiviral resistance to 
LET in subjects with clinically  
significant CMV infection from 
Week 14 post -transplant through
Week 48 post -transplant .Antiviral resistance to LET in 
prophy laxis failures
4 S TUDY DESIGN
4.1 Overall Design
This is a rand omized, placebo- controlled, parallel- group, multi -site, double -blinded, efficacy  
and safet y stud y of extending LET proph ylaxis in CMV R+HSCT recipients who have 
alread y received LET prophy laxis through Week 14(~100 days) post-transplant and who are
at high risk for CMV infection and/or disease thereafter .  This trial will enroll approximately  
216allogeneic CMV R+ HSCT recipients who have alread y received LET prophy laxis that 
started within 28 daysafter HSCT and continued through approximately  14weeks
post-transplant prior to randomization in this study . Eligible participants will be randomized 
in a 2:1 ratio to continue their L
ET treatment uninterrupted for an additional 14 weeks 
(~100 days of LET treatment for a total of 200daysof LET post-transplant )or to begin 
receiving placebo (a total of 100 days ofLET post-transplant ).  LET will be administered as 
either 480 mg QDor 240 mg QD for those participants who are receiving concomitant 
cyclosporin A (CsA) .  The LET dose is reduced to 240mg QDwhen coadministered with 
CsA based on an increase in LET exposures of approximately  2-foldin health yvolunteers 
(P010) and Phase 3 stud y (P001) .  Participants will receive 14 weeks of study  treatment 
through Week 28 post -transplant and be followed to Week 48 post -transplant to evaluate 
post-prophy laxis CMV infection events .  
In order to ensure safe study  conduct, an independent external Data Monitoring Committee 
(DMC) will be established for safety  evaluation.  The DMC will review safety  data at 
proposed time points outlined in Section 9.7 and as detailed in the DMC charter .  The DMC 
will review safety data, consider the overall risk and benefit of continuing the study  to study  
participants, and make a recommendation to the Sponsor to continue, modify , or end the 
study .  
An independent blinded Clinical Adjudication Committee (CAC) will be established for this 
study  to adjudicate all potential CMV disease cases as identified by site investigators or as 
otherwise described in the CAC charter. 
Participants who discont inue study  medication early  (ie,prior to Week 28post-transplant ) 
are intended to complete all remaining treatment period visits through Week 28
post-transplant , as well as all remaining visits through Week 48post-transplant as outlined in 
the Schedule of Activities (SoA) .  All scheduled study  visits will be completed regardless of 
when cessation of study  treatment occurs .   
  05DKLV
080V09
PRODUCT: MK-8228 30
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
A visiting nurse service may  be utilized (if locally  available and approved for use) for the 
Weeks 32and 3 6post-transplant visits in the follow- up phase of the study .  Refer to the 
nursing manual for additional details .
For participants who develop clinically  significant CMV infection , the participant should 
have a CMV Infection Visit . It is very  important to ensure that all procedures, as outlined in 
the S oA, are performed at the CMV I nfection Visit immediately prior to the initiation of 
treatment for CMV disease or initiation of PET . Such participants will continue to be 
followed in the study  (despite discontinuing study therap y,and if applicable, initiating anti -
CMV therap y) and are intended to complete all remaining study  visits (including all 
subsequent treatment period visits). 
Participants who discontinue the study prior to Week 48 post-transplant should complete an 
Early Discontinuation Visit.
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
areprovided in Section 8.
4.2 Scientific Rationale for Study Design
Population 
Overall, HSCT recipients who are CMV R+have increased non- relapse mortality  compared 
to CMV seronegative recipients [Teira, P., et al 2016] .  Additional risk factors for 
developing clinically  significant CMV infection bey ond the first 100 days post-transplant
that may  require extended CMV prophy laxis therapy  include HLA mismatch, T -cell 
depletion [Huang, Y. T., et al 2016] including the use of anti -thymocy te globulin ,receipt of 
cord blood allograft [Boeckh, M. and Nichols, W. G. 2004] or allograft from haploidenti cal 
donor, and recipients who have GV HD requiring the use of high dose steroids.  As such, 
CMV R+ HSCT recipients who have one or more of these high -riskfactors for developing 
clinically  significant CMV infection beyond 100 day s post-transplant are selected for this 
study .
Randomization and Stratification
Study  P001 demonstrated that L ET prophy laxis during the first 14 weeks after HSCT is 
effective and well -tolerated in preventing clinically significant CMV infection.  I n the 
present stud y, CMV R+ HSCT recipients who have received LET prophy laxis through 
Week 14post-transplant are randomized to receive either 14 weeks of LET or placebo until 
Week 28post-transplant .  The timing of randomization of participants at Week 14 
(~Day 100) post -transplant is selected to reflect the time the clinical decision is made of 
whether to extend the duration of CMV prophy laxis .  This study will randomize in a 2:1 ratio 
with a total of 216 participants with 1 44in the LET(200-day) arm and 72intheplacebo
(100-day) arm in order to allow more participants topotentially  benefit from LET 
prophy laxis .  Randomization will be stratified by study  center in order to balance varying 
clinical practices of PET initiation and ty pes of transplants at different centers.  In addition,  
  05DKLV
080V09
PRODUCT: MK-8228 31
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
randomization wi ll also be stratified by participants who received cells from a haploidentical 
donor , as this represents a defined large population with a baseline risk factor for CMV 
infection.  Note that it is possible that some sites will only  enroll participants with the same 
haploidentical donor status (either all y es or all no).   The number of participants who 
received cells from a haploidentical donor will be capped at ~30% of total participants.
Treatment Duration
A study  inrecipients of solid -organ transplants demonstrated that the incidence of CMV 
disease at 12 months post-transplant can be sig nificantly  reduced if 200days of proph ylaxis 
is implemented instead of 100 days[Humar, A., et al 2010] .  Similarly , the p rolongation of 
prophy laxis to Week 28post-transplant could be a potential strategy  to decrease the 
incidence of clinical significant CMV infection in certain HSCT recipients at high risk for 
CMV infection.  As such ,an additional 100 daysof LET or placebo bey ond the initial L ET 
prophy laxis after 100days post -transplant HSCT will be evaluated in HSCT recipients who 
areat high risk of CMV infection after 100 dayspost-transplant .  The proportion of clinically
signifi cant CMV infection will be assessed at the end of study therap y at Week 28
post-transplant as the primary  endpoint .
4.2.1 Rationale for Endpoints
4.2.1.1 Efficacy Endpoints
Theprimary efficacy  endpoint of the study  will be the proportion of participants with 
clinically  significant CMV infection post-transplant , which is defined as the occurrence of 
either one of the following outcomes: 
onset of CMV end -organ disease (probable or proven)
OR
initiation of anti -CMV PET with approved anti -CMV agents (ganciclovir, 
valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and 
the clinical condition of the participant
The composite endpoint of clinically  significant CMV infection used in study  P001was 
selected for this study  because CMV infection (as measured b y CMV viremia) is associated 
with increased morbidit y and mortality in HSCT recipients.  It is difficult to use CMV end-
organ disease alone as the sole clinical endpoint due to low incidence of CMV disease in 
HSCT recipients as a result of PET.  The results of P001 demonstrate that the composite 
endpoint of clinically  significant CMV infection is a relevant clinical endpoint [Marty , F. M., 
et al 2017] .The primary endpoint will be assessed at the end of stud y therapy (Week 28 
post-transplant ).  This endpoint will also be assessed at multiple time points post -transplant
as secondary  endpoints in order to describe the natural history  of clinically  signific ant CMV 
infection after an extended duration of LET prophylaxis .  
  05DKLV
080V09
PRODUCT: MK-8228 32
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
In this stud y, CMV DNA PCR testing will be measured from plasma samples using the
Roche COBAS®AmpliPrep/COBAS TaqMan®(CAP/CTM) assay , which will be performed 
by the central laboratory .  The lower limit of quantification (LLoQ) for this assay  is 
137IU/mL ,which is approximately  151copies/mL (using a conversion factor of 
1.1copies/IU as per the assay  package insert).  The CMV DNA levels in IU/mL  will be 
reported as one of the following:
<137 NOT DETECTED
<137 DETECTED NOT QUANTIFIABLE
A numeric value
>910,000,000
In this stud y, anyquantifiable CMV viral DNA result on a confirmatory  sample obtained 
immediately  prior to (i e, on the day  of) the initiation of treatment for CMV disease or PET 
using central CMV PCR assay  is acceptable for documenting viremia as a component of the 
efficacy  endpoint.  In addition to documented CMV viremia, the investigator should also take 
into account the clinical condition of the study participant when deciding to initiate PET.   
Quantifiable CMV viral DNA alone without initiation of anti- CMV therapy  will not be 
considered as a case for clinically  significant CMV infection in the primary  efficacy  anal ysis.
While any  quantifiable CMV viral DNA results in the Roche CAP/CTM assay  from 
confirmatory  plasma sample sent to the central laboratory  is acceptable for the purpose of 
documenting viremia as a component of the 
primary  endpoint, it is recom mended that 
investigators consider initiating PET when CMV DNA viral load is approximate ly 
>274 IU/mL or >300 copies/mL .  This threshold for initiation of PET is provided as guidance 
and is not mandated since a participant’s clinical condition and the need for PET is best 
assessed b y the investigator.
All cases of potential CMV disease will be determined using the definitions in Appendix 7
(Section 10.7) and confirmed by  an independent, blinded CAC.  The CAC w ill review 
clinical, virological, and histopathological data as well as the investigator’s assessment for 
adjudicating all potential cases of CMV disease.  The adjudication of cases by the CAC will 
take precedence over the investigator’s assessment for the purpose of analy sis.
4.2.1.2 Safety Endpoints
The safet y and tolerability of LET will be assessed by  a clinical evaluation of ad verse 
experiences and evaluation of other study parameters including vital signs, physical 
examination, and standard laboratory  safet y tests at appropriate time points .   
  05DKLV
080V09
PRODUCT: MK-8228 33
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
4.2.1.3 Other Endpoints
CMV Immune Response
CMV -specific T -cell immunity  is the predominant adaptive immune response that confers 
protection against CMV [Manuel, O., et al 2013] [Abate, D., et al 2013] [Cantisan, S., et al 
2013] [Fernandez -Ruiz, M., et al 2014] .  A d elayed recovery of T-cell immunity  
post-transplant has been observed with long -term viral suppression [Reusser, P., et al 1991] , 
which may potentially  lead to continued risk of CMV infection.  However, the association 
between antiviral proph ylaxis and delayed immune reconstitutions is inconsistent [Zaia, J. 
A., et al 1997] [Boeckh, M., et al 2006] .  Preclinical data suggest that treatment with LET is 
accompanied b y the cytoplasmic accumulation of large amounts of subviral, noninfectiou s 
particles termed dense bodies (DBs) within CMV -infected cells [Goldner, T., et al 2011] .  As
DBs are im munogenic and are known to prime l ymphocytes and neutralizing antibodi es in 
mice, it is possible thatthe release of noninfectious , immunogenic DB during LET 
prophy laxis may  facilitate the development of antiviral immune response following HSCT.  
In order to understand the impact that prolonged LET proph ylaxis has on the development of 
CMV -specific T -cell responses in individuals who are at high risk of clinically significant 
CMV infection/disease bey ond the initial 100days post -transplant , the correlation between 
the proportio n of participants who develop CMV- specific T- cell responses and clinically  
significant CMV infection in the L ET and placebo groups will be assessed as an exploratory  
endpoint in this study .  The proportion of participants with positive QuantiFERON -CMV 
assay  results will be correlated with the inci dence of clinically  significant CMV infection
through Week 48post-transplant and asses sed as an exploratory  endpoint.  
Health Outcome sAssessment
The occurrence and treatment of CMV infection is associated with significant resource 
utilization in the first 6 months post-transplant [Martin, P. J. 2008] .  Use of intravenous 
medications serve as a prox y meas ure of patient medication burden, especially  if they  need to 
travel to a healthcare facility  to receive the treatment .  It is important to collect healthcare 
resource utilization data since an extended duration of proph ylaxis will be accompanied by 
increas es in the total cost of the proph ylaxis regimen.  Pay ers, public healthcare s ystems, 
insurance providers, clinicians, and other decision makers will require data on health-
outcomes measures (such as incidence of all- cause mortality , rehospitalizations, GVH D, 
select opportunistic infections, intravenous medication use, and recurrent CMV infection) to 
inform anal yses of budget impact and cost effectiveness .  Clinical trials are important sources 
of health economic data as they have high internal validity  and can produce unbiased 
estimates of economic benefits .  As such, to evaluate if extended duration of L ET 
prophy laxis is associated with changes in the utilization of healthcare resources, healthcare 
resource utilization data are collected for all participant s throughout the study .  The data 
collected may  be used to conduct exploratory  economic anal yses. 
  05DKLV
080V09
PRODUCT: MK-8228 34
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
4.2.2 Rationale for t he Use of Comparator/Placebo
It has not yet been shown that there is clinical benefit to continuing CMV prophylaxis in 
HSCT recipients after 100 days post-transplant .  Therefore , the efficacy  and safet y of LET 
with monitoring/PET will be compared against placebo and monitoring/PET, which is the 
standard ofcare for CMV management for allogeneic HSCT recipients who are at risk of 
CMV infection/disease aft er Day  100 post-transplant.  The trial is designed to evaluate if 
LET is superior to placebo in the prevention of clinically  significa nt CMV infection when 
LET proph ylaxis is extended from 100 to 200days post-transplant .  The use of a placebo-
controlled design will also allow a robust evaluation of the safet y profile of L ET bey ond the 
initial 100 days post-transplant .  
4.3 Justification for Dose
Thedoses of LET selected in this study  are 480mg QD orally or intravenously, or 240mg 
QDorally or intravenously when coadministered with CsA. The L ET dose is reduced to 
240mg QD when coadministered with CsA based on the observed increase in LET
exposures in a Phase 1 DDI trial in health y subjects (P010) and Phase 3 study  (P001) .  These
LET doses have been approved for proph ylaxis of CMV in HSCT recipients.   Since the oral 
formulation of LET demonstrates no clinicall y significant food effect, participants may take 
the study  drug orally  without regard to food.  Refer to the IB for details on dose justification; 
the rationale for the doses selected is briefl y summarized in this section.
4.4 Beginning and End ofStudy Definition
The overall study  begi ns when the first participant signs the ICF. The overall study  ends 
when the last participant completes the last study -related telephone -call or visit, withdraws 
from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the 
investigator).
4.4.1 Clinical Criteria f orEarly Study Termination
Early study termination will be the result of the criterion specified below:
The DMC recommends termination of the study and the Executive Oversight 
Committee (EOC) agrees as stated in the DMC charter.
The clinical study may be terminated earl y if the extent (incidence and/or severit y) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study
population as a whole is unacceptable.  
Details for the discontinuation of study  medication for an y given participant are provided in 
Section 7.1. 
  05DKLV
080V09
PRODUCT: MK-8228 35
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
5 STUDY POPULATION
Male and female CMV R+ participants of at least 18 y ears of age who had an allogeneic
HSCT a nd have received LET as primary CMV prophy laxis that started within 28 daysof 
HSCT and continued through 14 weeks post -transplant willbe enrolled in this study .  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criteria apply:
1.have d ocumented positive CMV serostatus (CMV IgG seropositive) for recipient (R+) at 
the time of transplant .
2.history  ofallogeneic HSCT (bone marrow, peripheral blood stem cell, or cord blood 
trans plant) within ~100 day s prior to randomization .
3.have undetectable CMV DNA or detec table/ not quantifiable CMV DNA (central 
laboratory ) from a plasma sample collected within 14daysprior to randomization.
4.have received LET as primary proph ylaxis that started within 28 daysof HSCT and 
continued through Week 14post-transplant (100days) ±1week prior to randomization .
5.athigh risk of CMV disease ,defined as meeting one or more of the following criteria :
a.having a related donor with at least one mismatch at one of the specified three HLA 
gene loci (HLA -A, B, or DR); 
b.having an unrelated donor with at least one mismatch at one of the specified four 
HLA gene loci (HLA -A, B, C, and DRB1); 
c.having a haploidentical donor; 
d.having umbilical cord blood as the stem -cell source; 
e.having ex-vivo T-cell–depleted grafts;
f.receipt of anti -thymocy te globulin (Note: e nrollment of participants whose ONLY 
high-risk factor is the use of anti -thymocy te globulin will be restricted to 20% of all 
enrolled participants);
g.receipt of alemtuzumab ;
h.having GVHD or other conditions, requiring the use of systemic prednisone (or 
equivalent) at a dose of ≥1 mg /kg ofbody  weight per day  within 6 weeks of 
randomization. 
  05DKLV
080V09
PRODUCT: MK-8228 36
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Demographics
6.Participant is ≥18yearsof age at the time of signing the informed consent.
Female Participants
7.A female participant is eligible to participate if she is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of th e following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 .
OR
b.A WOCBP who agrees to follow the contraceptive guidance i n Appendix 5 during the 
treatment period and for at least 28daysafter the last dose of study  medication .
Informed Consent
8.The participant (or legally acceptable representative if applicable) provides written 
informed consent for the study .  
5.2 Exclusion Criteria
Parti cipants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.has a history  of CMV end -organ disease or preemptive treatment therap y for CMV after 
HSCT prior to randomization.
2.has a history  of > 14days total of LET interruption during the first 100 day s 
post-transplant prior to randomization .
3.has suspected or known hy persensitivity  to active or inactive ingredients of L ET 
formulations.
4.has severe hepatic insufficiency  defined as Child -Pugh Class C ( see Append ix8, 
Section 10.8) within 14daysprior to randomization.
5.has serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 ×the 
upper limit of normal (ULN) within 14daysprior to randomization.  
Note : Participants who meet this exclusion criterion may, at the discretion of the 
investigator, have repeat testing done one time prior to randomization .  If the repeat 
value does not meet this criterion, they  may  continue in the screening process.  Only  
the specific out of range value should be r epeated (not the entire panel). 
  05DKLV
080V09
PRODUCT: MK-8228 37
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
6.has end -stage renal impairment with a creatinine clearance less than 10 mL/min, as 
calculated b y the Cockcroft -Gault equation using serum creatinine within 14 daysprior to 
randomization
Creatinine Clearance (Males) = weight in kg ×(140 –agein years)
72×serum creatinine in mg/dL
Creati nine Clearance (Females) = 0.85× the value obtained with formula above
Note : Participants who meet this exclusion criterion may , at the discretion of the 
investigator, have repeat testing done one time within 14daysprior to randomization .  
If the repeat value does not meet this criterion, they may continue in the screening 
process.  Onl y the specific out of range value should be repeated (not the entire 
panel).
7. has both moderate hepatic insufficiency  AND moderate -to-severe renal insufficiency . 
Note: Moderate hepatic insufficiency  is defined as Child -Pugh Class B (see 
Appendix 8); moderate- to-severe renal insufficiency  is defined as a cr eatinine 
clearance less than 50 mL/min, as calculated by t he Cockcroft -Gault equation (as 
above), respectivel y.
8.has an uncontrolled infection on the day  of enrollment.
9.requires mechanical ventilation or is hemody namically  unstable at the time of enrollment.
10.has a documented positive resu lt for a human immun odeficiency  virus antibody  
(HIV -Ab) test at an y time prior to screening , or for hepatitis C virus ant ibody  (HCV -Ab) 
with detectable HCV RNA, or hepatitis B surface antigen (HBsAg) within the6months 
prior to screening .
11.has active solid tumor malig nancies ( with the exception of localized basal cell or 
squamous cell skin cancer ). 
  05DKLV
080V09
PRODUCT: MK-8228 38
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Prior/Concomitant Therapy
12.Received within 7 daysprior to screening an y of the following:
ganciclovir or valganciclovir
foscarnet
acyclovir (at dose s greater than those recommended for HSV/VZV proph ylaxis; see 
Sec. 6.5.2.1)
valacy clovir (at dose s greater than those recommended for HSV/VZV prophy laxis ;
see Sec. 6.5.2.1 ) 
famciclovir (at doses greater than those recommended for HSV/VZV prophylaxis; 
see Sec. 6.5.2.1)
13.Received within 30 daysprior to screening an y of the following:
cidofovir
CMV immunoglobulin 
Prior/Concurrent Clinical Study Experience
14.is currentl y participating or has participated in a study with an unapproved investigational 
compound, monocl onal antibody ,or device within 28 day s or 5×half-life of the 
investigational compound or monoclonal antibody , whichever is longer, of initial dosing 
in this study .  
Note : Investigational chemotherapy  regimens involving approved agents and 
investigational antimicrobial regimens involving approved 
antibacterial/antifungal/antiviral agents, investigational radiotherap y or GVHD 
agents , or other observational studies are allowed .
15.has previousl y participated in this study  or any  other study  involving LET ,or is currentl y 
participating in an y study involving administration of a CMV vaccine or another CMV 
investigational agent, or is planning to participate in a study of a CMV vaccine or another 
CMV investigational agent during the course of this study .
Other Exclusions 
16.is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the 
time of consent through 28daysafter the last dose of study  therapy .
17.is expecting to donate eggs starting from the time of consent t hrough 28 daysafter the 
last dose of study  therapy. 
  05DKLV
080V09
PRODUCT: MK-8228 39
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
18.has clinically  relevant drug or alcohol abuse within 12 months of screening that may  
interfere with participant treatment, assessment, or compliance with the protocol as 
assessed b y the investigator .
19.hasa history  or current evidence of an y condition, therap y, lab abnormality ,or other 
circumstance that might confound the results of the study, interfere with the participant’ s 
participation for the full duration of the study, or would be put at undue risk as judged b y 
the investigator, such that it is not in the best interest of the participant to participate in 
this study .
20. i s or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly  involved with this study .
5.3
Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
The oral formulation of LET demonstrates no clinically significant food effect, thus 
participants may  take the study  drug orally  without regard to food.   However, there may  be 
restrictions with other nonstudy treatment agents the participant is taking during the stud y 
and therefore i t is important for investi gators to refer to the product information for those 
agents (ie,participants who are taking CsA c oncomitantly  with L ET must avoid consumption 
of grapefruit and grapefruit juice ).  
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently rando mized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities . Min imal information includes demograph y, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who discontinues from study  medi cation orwithdraws from the study will not 
be replaced . 
  05DKLV
080V09
PRODUCT: MK-8228 40
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or 
medical device(s) intended to be administered to a study  participant accord ing to 
the study  protocol.
Clinical supplies ,study intervention (s) provided by the Sponsor will be packaged to support 
enrollment .  Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements.
6.1 Study Intervention(s) Administered
The study  medication (s) to be used in this study  are outlined in Table 1(oral formulation) 
and Table 2(IV formulation).  Both the 240 -mg (for participants on CsA) and 480 -mg (for 
participants not on CsA) oral formulations of LET will be made available by the Sponsor. 
Approximately  216participants who have received LET through 100 days post-transplant are 
planned for randomization in a 2:1 ratio to receive either an additional 100 days(14weeks ) 
of once -daily  LET (n=1 44participants) or placebo (n= 72participants) from the day  of 
enrollment (Day  1—ie,100days[14weeks ] post-transplant ) through 28 weeks
post-transplant .  
Participants on 480 mg will receive either one 480 -mg tablet or two 240 -mg 
tablets (based on the participants’ tolerance to swallowing the larger 480 -mg tablet).  The IV 
formulation of LET will be available for participants randomized to L ET who develop a 
condition that may  interfere with their ability  to swallow, or a condition that interferes with 
the absorption of the oral formulation (eg, vomiting, diarrhea, or a malabsorptive cond ition).  
Participants randomized to placebo who develop a condition that may interfere with their 
ability  to swallow, or a condition that interferes with the absorption of the oral formulation 
will be able to receive IV administration of placebo.  The simultaneous use of IV and oral 
study  therapy  is not permitted.  Use of the IV formulation should generall y be limited to a 
duration of 4 weeks or less; however, IV administration bey ond 4 weeks will be permitted if, 
in the investigator’s judgment , the benefit /risk supports continued administration.  There is 
no sponsor -provided placebo for IV LET .  On -site blinding will be administered b y an 
unblinded pharmacist using open label IV LET (20 mg/m L, 12-mLfill vial) and locall y 
supplied sterile IV dextrose or sal ine diluent as the placebo. 
  05DKLV
080V09
PRODUCT: MK-8228 41
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table 1 Study  Therapy  –Oral (Tablet) Formulation
DrugDose/
PotencyDose 
FrequencyRoute of 
AdministrationRegim en/
Treatm ent PeriodUseIMP/ 
NIMPa Sourcing
LET (for participants 
on CsA)240 m g Once daily OralFrom Week 14 post-transplant
to Week 28 post-transplantExperimental IMP Sponsor
LET (for participants 
not on CsA)480 m g (one 480-
mg tablet or two 
240-mg tablets)Once daily OralFrom Week 14 post-transplant
to Week 28 post-transplant Experimental IMP Sponsor
Placebo for LETbNA Once daily OralFrom Week 14 post-transplant
to Week 28 post-transplantPlacebo IMP Sponsor
CsA = Cyclosporin A; I MP = investigational medicinal product; LET = letermovir; NIMP = noninvestigational medicinal product 
a: The classification of I nvestigational Medicinal Product (I MP) and Non -Investigational Medicinal Product (NI MP) in this table is based on guidance issued by the European Commission and 
applies to countries in the European Economic Area (EEA). Country differences with respect to the definition/classification o f IMP/NI MP may exist. In these circumstances, local legislation is 
followed .
b: The number of placebo tablets will mimic the LET dosing scheme in an effort to maintain the blind (ie, 1 matching placebo tab let if on CsA; 1 or 2 matching placebo tablets if not on CsA to 
mimic one 480 -mg tablet or two 240 -mg tablets, respectively).
Table 2 Study  Therapy  –Intravenous Formulation
DrugDose/
PotencyDose 
FrequencyRoute of 
AdministrationRegim en/
Treatm ent PeriodUseIMP/ 
NIMPa Sourcing
LET (for participants 
on CsA)b 240 m g Once daily IVFrom Week 14 post-transplant to 
Week 28cpost-transplantExperimental IMP Sponsor
LET (for participants 
not on CsA)b 480 m g Once daily IVFrom Week 14 post-transplant to 
Week 28cpost-transplantExperimental IMP Sponsor
Placebo for LETbNA Once daily IVFrom Week 14 post-transplant to 
Week 28cpost-transplantPlacebo IMP Site locally
CsA = Cyclosporin A; I MP = investigational medicinal product; LET = letermovir; NI MP = noninvestigational medicinal product 
a: The classification of Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NI MP) in this table is based on guidance issued by the European Commission and 
applies to countries in the European Economic Area (EEA). Country differences with respect to the definition/classification o f IMP/NI MP may exist. In these circumstances, local legislation is 
followed .
b: LET IV formulation dosing volume is 250 mL and duration of infusion will be 60 minutes. LET IV will be provided as a sterile liquid concentrate for dilution (20 mg/mL), one vial t o be used 
for the 240 -mg dose and two vials for the 480 -mg dose. Locally supplied sterile IV dextrose or saline diluent will be used as the placebo to LET IV as prepared by the site unblinded pharmacist.
c: The IV formulation should be switched to oral study therapy (ie, at the next planned dose) as soon as participants are able to swallow and/or the condition necessitating t he use of the I V 
formulation resolves. 
  05DKLV
080V09
PRODUCT: MK-8228 42
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
All supplies indicated in Table 1and Table 2will be provided per the "Sourcing" row 
depending upon local country  operat ional requirements. Every  attempt should be made to 
source these supplies from a single lot/batch number. The stud y site is responsible for 
recording the lot number, manufacturer, and expiry date for an y locall y purchased product 
per local guidelines unles s otherwise instructed b y the Sponsor.
Refer to Section 8.1.8 for details regarding administration of the study intervention.
All placebos were created by  the Sponsor to match the active product.
6.2 Preparation/Handling/Storage/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4.3. 
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and an y discrepancies are 
reported and resolved before use of the stud y intervention .
Only  participants enrolled in the study  may  receive study  intervention , and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or aut omated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for dru g accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is respo nsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any applicable laws and regulations. 
  05DKLV
080V09
PRODUCT: MK-8228 43
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
6.2.3 Participant -level Study Medication Accountability 
The investigator/study  coordinator will train the participant in the use of the Study  
Medication Diary .  The participant will be instructed to record the number of tablets of study  
therap y taken during the study therap y period.  At visits when used/unused st udy therapy  are 
returned, site personnel must verify  the accuracy  of the dosing diary  by comparing entries 
with amounts of returned study  therapy .  If a discrepancy  is noted, the investigator/study  
coordinator must discuss the discrepancy with the particip ant, and the detailed explanation 
must be documented in the participant’s stud y record.  The investigator/study coordinator 
will be responsible for transferring the appropriate information to the case report form.
6.3 Measures to Minimize Bias: Randomization a nd Blinding
6.3.1 Intervention Assignment
Intervention allocation/randomization will occur centrally  using an interactive response 
technology  (IRT) s ystem.  There are 2 study  medication arms .  Participants wi ll be 
randomized 2:1 to receive either LET (dosage of 240mg or 480 mg dependent on CsA 
status) or placebo for LET.
6.3.2 Stratification
Treatment allocation/randomization will be stratified by:
1)study center and 
2)haploidentical donor (yes/no)
6.3.3 Blinding
In this stud y a double -blinding technique with in -house blinding will be used.  The 
participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the 
study  medication administration or clinical ev aluation of the participants a re unaware of the 
intervention assignments.
Oral LET tablets will be packaged identicall y so that treatment blind/masking is maintained.  
A placebo image to LET (both 240 mg and 480 mg) will be implemented to maintain study  
blinding and placebo tablets wil l be indistinguishable from LET.  Participant s on CsA will 
receive either 1tablet of 240 mg LET or 1 tablet of matching placebo.  Participants not on 
CsA will receive either 480 mg LET (administered as 1tablet of 480 mg LET or 2tablets of 
240mg LET) or 1 or 2tablets of matching placebo.
IV LET matching placebo (see Section 6.1) will be prepared in a blinded fashion by  an 
unblinded pharmacist (or qualified study site personnel designated to prepare blinded IV 
study  therapy ).  The unblinded pharmacist wi ll obtain the IV treatment assignment from I RT.  
The Sponsor will provide opaque covers for the IV bags in order to assist with blinding IV 
study  therapy . 
  05DKLV
080V09
PRODUCT: MK-8228 44
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Because this is a double -blind study , the investigator, study  personnel, and participant must 
remain blinded to the IV study  therapy .  In order to maintain the blinding, the unblinded 
pharmacist (or qualified study site personnel designated to prepare blinded IV study therap y) 
will be responsible solely for the preparation of the IV stud y therap y.  He/she will not be 
involved in evaluating participants for efficacy  or safet y.  The IV stud y therapy will be 
administered b y blinded personnel of the site.  Refer to the Pharmacy Manual for further 
details.
Patients who have their treatment inadvertently unblind ed will not be discontinued from the 
study .
6.4 Study Intervention Compliance
Interruptions from the protocol specified treatment for ≥7daysrequire consultation between 
the investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
6.5 Concomitant Therapy
It is important for investigators to review each medication (prescription and non- prescription) 
the participant is taking before starting the study and at each stud y visit.
At each visit, participants should be questioned about any new drug they are taking.
To minimize the risk of adverse drug interactions, every  effort should be made to 
limit the number of concomitant drugs to those that are trul y essential.
Given that the lists below are not comprehensive, the investigator should use his/her medical 
judgment when a participant presents with a medication not on the list and consult with the 
Sponsor when appropriate.
6.5.1 Allowed Medications/Therapies to be Administered with C linical and/or Drug 
Level Monitoring when Coadministered with Study Therapy
The following medications/therapies are allowed when coadministered with study  therapy , 
but should be used with clinical monitoring for AEs related to these agents and/or drug level 
monitoring of these agents (please refer to the prescribing information of each local product 
circular ). 
  05DKLV
080V09
PRODUCT: MK-8228 45
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Note: Since the drug -drug interactions may be different when LET is coadministered
with CsA than when drugs are co administered with LET without CsA , please refer to 
Section 6.5.2.2 for additional recommendations when study therapy is coadministered
with CsA.
CYP3A substrates :
Coadministration of LET with drugs that are CYP3A substrates may result in 
clinically  relevant increases in the plasma concentrations of co -administer ed 
CYP3A substrates (eg, alfentanil, fentan yl, and midazolam ).  Therefore, frequent 
monitoring for adverse reactions relat ed to these agents is recommended during 
coadministration .  
Dose adjustment of CYP3A substrates with narrow therapeutic range ( NTR) may 
be needed when coadministered with LET (a moderate CYP3A inhibitor) .  Please
consult current prescribing information fo r monitoring and dosing of these 
products with moderate inhibitors of CYP3A .
Cyclosporin A(CsA) :  Co administration of LET with CsA increases CsA 
concentrations.  Frequent monitoring of CsA whole blood concentrations 
should be performed during and at disco ntinuation of L ET with the dose of 
CsA to be adjusted a s appropriate .
Sirolimus :  Co administration of LET with sirolimus increases concentrations 
of sirolimus.  Frequent monitoring of sirolimus whole blood concentrations 
should be performed during and at discontinuation of L ET with the dose of 
sirolimus to be adjusted a s appropriate.  When LET is co- administered with 
CsA, refer to the sirolimus prescribing information for specific dosing 
recommendations for use of sirolimus with CsA.
Tacrolimus :  Co administration of LET with tacrolimus increases tacrolimus 
concentrations.  Frequent monitoring of tacrolimus whole blood 
concentrations should be performed during and at discontinuation of L ET with
the dose of tacrolimus to be adjusted a s appropriate .
Everolimus:  Co administration of LET with everolimus may  increase 
everolimus concentrations.  Frequent monitoring of everolimus blood 
concentrations should be performed during and at discontinuation of L ET with
the dose of everolimus to be adjusted as appropriate .  (Note : Please see 
Section 6.5.2.2 for recommendation of everolimus when LET is co -
administered with CsA).
Amiodarone :LET may  increase the plasma concentrations of amiodarone 
(CYP3A and CYP2C8 substrates) .  Frequent monitoring for adverse reactions 
related amiodarone is recommended during coadministration .  Frequent 
monitoring of amiodarone concentrations should be performed when co -
administered with LET . 
  05DKLV
080V09
PRODUCT: MK-8228 46
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Certain HMG -CoA reductase inhibitors ( statins) as s ubstrates of organic anion -
transporting polypeptide 1B1/3 (OATP1B1/3) and/or CYP3A:
Atorvastatin:  The dose of atorvastatin should not exce ed a dail y dose of 20 mg.  
(Note : Please see Section 6.5.2.2 for recommendation of atorvastatin when LET is 
co-administered with CsA )
Fluvastatin, lovastatin, rosuvastatin, or pravastatin :  The dose of fluvastatin, 
lovastatin, rosuvastatin, or pravastatin may  need to be adjusted when co -
administered with LET .  Monitoring for statin- associated adverse reactions (eg, 
myalgias, rhabdom yolysis) is recommended during co -administration with LET. 
Substrates of CYP2C9 and CYP2C19 (voriconazole, warfarin, phenytoin , 
omeprazole, and pantoprazole):
Voriconazole :  Co -administration of L ET with voriconazole decreases the plasma 
concentrations of voriconazole likely due to induction of CYP2C9 and/or 2C19.  
If concomitant administration is necessary , close monitoring for reduced 
effectiveness of voriconazole is recommended.
Warfarin:  LET may  decrease the plasma concentrations of CYP2C9 and/or 
CYP2C19 substrates (eg, warfarin).   Frequent monitoring of international 
normalized ratio (INR) should be performed while warfarin is co- administered 
with L ET.
Proton Pump I nhibitors, omeprazole, and pantoprazole :  LET may decrease the 
plasma concentrations of CYP2C19 substrates. Clinical monitoring and dose 
adjustment may  be needed.
Medications for Diabetes:   
Glyburide, repaglinide, or rosiglitazone :  LET may increase the plasma 
concentrations of these diabetic medications .  Frequent monitoring of glucose 
concentrations is recommended during co- administration with L ET.  (Note : 
please see Section 6.5.2.2 for recommendation of repaglinide when LET is co-
administered with CsA )
6.5.2 Prohibited Medication s
Medications/therapies that are prohibited during coadministration with study therap yduring 
the time periods specified are outlined in Section 6.5.2.1 .  Since the dr ug-drug interaction on 
co-administered drugs may  be different when LET is co- administered with CsA than when 
drugs are co -administered with L ET without CsA, additional prohibited medications when 
study  therapy is co- administered with CsA are outlined in Section 6.5.2.2 . 
  05DKLV
080V09
PRODUCT: MK-8228 47
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Study  therapy should be administered in a manner consistent with the LET local product
circular , including the complete list of prohibited medications (ie, those that are 
contraindicated or not recommended) in the circular .  The local p roduct circular for LET 
supersedes this section when the product circular is more restrictive .
If there is a clinical indication for one of these or other medications specifically prohibited 
during the study , discontinuation from study  therapy may be requi red.  The investigator 
should discuss any  questions regarding this with the Sponsor .  The final decision on any  
supportive therap y rests with the investigator and/or the participant’ s primary  physician.  
However, the decision to continue the participant onstudy  therapy  requires the mutual 
agreement of the investigator, the Sponsor, and the participant.  Given that the list below is 
not comprehensive, the investigator should use his/her medical judgment when a participant 
presents with a medication not on the lis t and consult with the Sponsor.
6.5.2.1 Medications Prohibited with Study Medication
Antiviral drugs or therapies for prevention/treatment of CMV are prohibited during 
the study (Week 14to 48 post-transplant ), including but not limited to :
letermovir that is not part of study  medication
ganciclovir or valganciclovir
foscarnet
cidofovir
acyclovir (at doses greater than those recommended for HSV/VZV proph ylaxis, 
such as >3200 mg PO per day  or >25 mg/kg IV per day )
valacy clovir (at doses greater than those recommended for HSV/VZV 
prophy laxis, such as >3000 mg)
famciclovir ( at dose s greater than those recommended for HSV/VZV prophy laxis , 
such as >1500 mg ) 
CMV immun oglobulin 
any investigational CMV antiviral agent/biologic therap y, including CMV 
vaccines
Note: these agents may  be used for other indications while participants are on 
study  therapy (eg, foscarnet for the treatment of HHV -6 or acy clovir for treatment 
of disseminated zoster ) 
  05DKLV
080V09
PRODUCT: MK-8228 48
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
The following medications/therapies are prohibited duri ng the dosing period and for 
14days after study medication is discontinued : 
Investigational Agents :  Unapproved investigational agents or investigational 
regimens involving combinations of approved agent sarenot permitted except
Investigational chemotherap yregimens involving approved agents and 
investigational antimicrobial regimens involving approved 
antibacterial/antifungal/antiviral age nts, investigational radiotherap y studies, or 
other observational studies are allowed.
Herbal Supplements :  Herbal supple ments are not permitted.
CYP3A substrates with NTR , including but not limited to:
Pimozide: Concomitant administration of L ET may  result in increased 
concentrations of pimozide due to inhibition of CYP3A by  LET, which may  lead 
to QT prolongation and torsade de pointes.
Ergot alkaloids: Concomitant administration of LET may  result in increased 
concentration of ergot alkaloids (ergotamine and dihydroergotamine) due to 
inhibition of CYP3A by  LET, which may  lead to ergotism.
Certain H MG-CoA reductase inhibitors ( statins) (Note: See Section 6.5.2.2 . for 
additional statins that are prohibited for use w hen LET is co administered with CsA) :
Simvastatin and pitavastatin
Fixed dose combinations of statins
Strong inducers , such as rifampin, phen ytoin, carbamazepine, St John’s wort 
(Hypericum perforatum), rifabutin and phenobarbital 
Moderate inducers , such asnafcillin, thioridazine, modafinil and bosentan
6.5.2.2 Additional Medications Prohibited When Study Medication is 
Co-administere d with CsA
Themagnitude of CYP3A- and OATP1B1/3 -mediated drug interactions on co -administered 
drugs may  be different when LET is co -administered with CsA than when drugs are co -
administered with LET without CsA .  In addition to the prohibited medications listed above 
in Section 6.5.2.1, m edications listed in this section are additional medications that are 
prohibited when coadminist ered with LET andCsA during the dosing period and for 14 day s 
after the dosing period.  When used together, they should be administered in a manner 
consistent with the local product circulars (for CsA and LET), including the complete list of 
prohibited me dications including those that are contraindicated or not recommended.  The  
  05DKLV
080V09
PRODUCT: MK-8228 49
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
local product circular for LET supersedes this section when the product circular is more 
restrictive .
Certain HMG -CoA reductase inhibitors (statins) :When L ET is co -administered wi th 
CsA, the magnitude of the increase in statin plasma concentrations is expected to be 
greater than with LET alone.  
atorvastatin and lovastatin ( Note : please see Section 6.5.2.1 for additional 
prohibited statins when coadministered with LET alone).  
Everolimus (Note: please see Section 6.5.1 for recommendation of everolimus when 
co-administ ered with LET alone)
Repaglinide ( Note: please see Section 6.5.1 for recommendation of repaglinide when 
co-administ ered with LET alone )
6.5.3 Rescue Medications and Supportive Care
In the event of clinically  significant CMV infection (CMV disease or initiation of PET based 
on CMV viremia and the clinical condition of the participant ) at an y time during the 28-week
post-transplant period, study  therapy  will be discontinued, and the participant may be treated 
according to the local standard of care (outside the context of the study ).  In this setting, an y 
of the prohibited anti -CMV medications (outlined in Section 6.5) may be used.
6.6 Dose Modification (Escalation/Titration/Other)
See Section 4.3for the LET dose to be used with or without co -administered CsA.
If CsA is initiated after starting study  medication , the next dose of the study  medication
should be decreased to 240 mg once daily.  If CsA is di scontinued permanently  or for the 
long term in a participant alread y receiving study  medication , the next dose of study  
medication should be increased to 480 mg once daily .  If CsA is temporarily withheld due to 
high levels detected b y therapeutic blood mo nitoring, the dose o fstudy  medication need not 
be adjusted.
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
The emergency  unblinding call center will use the int ervention /randomization schedule for 
the study  to unblind pa rticipants and to unmask study  medication identity .  The emergency  
unblinding call center should only  be u sed in cases of emergency (see Section 8.1.10) .  In the 
event that the emergency unblindi ng call center is not available for a given site in this study , 
the central electroni cintervention allocation/randomization sy stem (IRT) should be used to  
  05DKLV
080V09
PRODUCT: MK-8228 50
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
unblind participants and to unmask study  medication identity .  The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
6.9 Standard Policies
At the close of the stud y after unblinding, a letter is to be sent by the investigator to those 
participants who received placebos in the image of the investigational medicina l product 
(IMP) to provide the following advice:
“You have participated in a study  conducted b y the Sponsor .  This letter is to advise y ou that 
you were among tho se who received a look- alike tablet created b y the Sponsor to resemble 
the drug letermovir as much as possible .  You did not receive the active drug letermovir as 
manufactured b y MSD .”
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
Discontinuation of study  intervention does not represent withd rawal from the study .
As certain data on clinical events bey ond study  intervention discontinuation may  be 
important to the study , they  must be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study  intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 1.3 and 
Section 8.12.3.
Participants may  discon tinue study  intervention at any  time for any  reason or be d iscontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  the 
investigator or the Sponsor if study intervention is inappropriate, the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8 .1.9.
A participant must be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
The participant or participant’s legall y acceptable representative requests to 
discontinue study  interventi on.
The participant has a medical condition or personal circumstance which, in the 
opinion of the investigator and/or Sponsor, placed the participant at unnecessary  risk 
from continued administration of study  intervention.
The participant has a confirmed positive serum pregnancy  test. 
  05DKLV
080V09
PRODUCT: MK-8228 51
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
The investigator feels it is in the best interest of the participant to discontinue.
The participant develops clinically  significant CMV infection as determined by  the 
investigator ( Section 4.2.1.3).
The participant develops one of the following:
-Both moderate hepatic insufficiency  (Child -Pugh Class B; Sections 8.3.4 
and10.8) and moderate -to-severe renal insufficiency  (defined as CrCl 
<50mL/min as calculated by the Cockcroft -Gault equation) , 
OR
-Severe hepatic insufficiency  (Child -Pugh Class C; Sections 8.3.4 and 1 0.8)
Needs dial ysis or develops end -stage renal impairment with creatinine clearance 
≤10mL/min as calculated by  the Cockcroft -Gault equation as follows:
Creatinine Clearance (Males) = weight in kg ×(140 –agein years)
72×serum creatinine in mg/dL
Creati nine Clearance (Females) = 0.85× the value obtained with formula above
Note: Child -Pugh class (see Appendix 8) and creatinine clearance using the 
Cockcroft -Gault equation should be assessed at the Day  1 and every  visit until 
the study  medication is discontinued (including at the CMVi or Earl y 
discontinuation visit if study medication is being discontinued at those visits) in 
order to ensure timely  discontinuation of study  medication.
The participant may be discontinued from study  medication for an y of the following 
reasons:
Any AE/SAE assessed by  the investigator as related to study  therap y.  The 
investigator may continue the participant in the study  if it is deemed to be in the best 
interest of the participant to stay on stud y therap y.
Failure to compl y with the dosing, evaluations, or other requirements of the study.
The participant has a medical condition or personal circumstance which, in the 
opinion of the investigator and/or Sponsor, does not allow the participant to adhere to 
the requirements of the protocol (eg, if there is a clinical indication for an y 
medication or vaccination specificall y prohibited during the trial, discontinuation 
from trial therap y may be required [see Section 6.5]).
For participants who are discontinued from study  medication but continue to be monitored in 
the study , all visits and procedures, as outlined in the SoA, should be completed. 
  05DKLV
080V09
PRODUCT: MK-8228 52
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Note: Participants who have their treatment unblinded should not be discontinued from the 
study .
Participants may be allowed to begin study  medication again if deemed medicall y 
appropriate unless the participant’s treatment assignment has been unblinded by  the 
investigator, delegate, and/or nonstudy treating phy sician. There may  be instances where 
confirmatory  central lab oratory test results for CMV DNA PCR results obtained on the day  
of PET initiation may  be CMV DNA undetectable ordetected, but not quantifiable , and the 
investigator may  wish to discontinue PET.  The decision to stop PET resides with the 
investigator caring for the subject .  Therefore, in theevent theconfirmatory CMV DNA 
sample at PET initiation is CMV DNA undetectable or detected, but not quantifiable ,the 
Sponsor will allow for study  therapy  to be restarted at the investigator’s discretion, once PET 
is discontinued.  In such instances, study  therap y should be restarted within 7 days from the 
date o n which stud y therapy was stopped .  It is important to note that the status of the 
subject’s study therapy in IR Tshould NOT be changed until the CMV DNA PCR 
result is confirmed and the investigator is certain that study therapy will be 
permanently discont inued.
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study, they will no longer receive stud y treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,are outlined in Section 8.1.9. The procedures to be performed should a participant 
repeatedly  fail to return for scheduled visits and/or if the study  site is unable to contact the 
participant are outlined in Section 7.3.
7.3 Lost t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unabl e 
to contact the participant, the following procedures are to be performed:
The site must attempt to contact the participant and reschedule the missed visit. I f the 
participant is contacted, the participant should be counseled on the importance of 
maintain ing the protocol -specified visit schedule.
The investigator or designee must make every  effort to regain contact with the 
participant at each missed visit (eg, telephone calls and/or a certified letter to the 
participant’s last known mailing address or loc ally equivalent methods). These 
contact attempts should be documented in the participant’s medical record. 
  05DKLV
080V09
PRODUCT: MK-8228 53
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Note: A participant is not considered lost to follow -up until the last scheduled 
visit for the individual participant. The missing data for the parti cipant will be 
managed via the prespecified statistical data handling and anal ysis guidelines.
8 STUDY ASSESSMENTS AND PROCEDURES
Study  procedures and their timing are summarized in the SoA.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
The investigator is responsible for ensuring that procedures are conducted by 
appropriatel y qualified or trained staff. Delegation of study site personnel 
responsibilities will be documente d in the Investigator Trial File Binder (or 
equivalent).
All study -related medica l decisions must be made by  an investigator who is a 
qualified phy sician .
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable.
Procedures conducted as part of the participant’s rou tine clinical management (eg, 
blood count) and obtained before signing of I CF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol- specified criteria and were 
performed within the time frame defined in the SoA.
Additio nal evaluations/testing may  be deemed necessary  by the investigator and or 
the Sponsor for reasons related to participant safety. In some cases, such 
evaluation/testing may  be potentially  sensitive in nature (eg, HIV, Hepatitis C), and 
thus local regulations may  require that additional informed consent be obtained from 
the participant. In these cases, such evaluations/testing will be performed in 
accordance with those regulations .
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 255 mL; see Appendix 2(Section 10.2).
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples. 
  05DKLV
080V09
PRODUCT: MK-8228 54
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medicall y qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant or each participant’s legall y 
acceptable representative prior to participating in a clinical study .  If there are changes to the 
partic ipant’s status during the study (eg, health or age of majority requirements), the 
investigator or medicall y qualified designee must ensure the appropriate consent is in place.
8.1.1.1 General Informed Consent
Consent must be documented by  the participant’s dated s ignature or b y the participant’s 
legally  acceptable representative’s dated signature on a consent form along with the dated 
signature of the person conducting the consent discussion.
A cop y of the signed and dated consent form should be given to the partic ipant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opinion in advance of use. The participant or his/her legall y 
acceptable representative should be informed in a timely  manner if new information becomes 
available that may  be relevant to the participant’s willingness to continue partici pation in the 
study . The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the participant’s dated 
signature or b y the participant’s legally acceptable repres entative’s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requiremen ts.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator who is a qualified 
physician to ensure that the participant qualifies for the study . 
  05DKLV
080V09
PRODUCT: MK-8228 55
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.1.3 Participant Identification Ca rd
All participants will be given a participant identification card identify ing them as participants 
in a research stud y. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an emergency . The in vestigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
interventi on in emergency  situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  the investigator or qualified designee at screening .
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qu alified designee will review prior medication use, including an y 
protocol -specified washout requirement .  Prior medication s such as antivirals, chemotherap y 
agents, and immunosuppressant agents taken by  the participant 30 day s prior to screening 
should be recorded .
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication s, if an y, taken by the 
participant during the study treatment through 2 weeks after the stud y medication is 
discontinued.  In addition, a nti-CMV medications (in cluding LET that is not part of the study  
medication , ganciclovir, valganciclovir, acy clovir, valacy clovir, famciclovir, foscarnet, 
cidofovir) administered for treatment of CMV disease or for initiation of PET, and all 
drug/biologic therapies used to preve nt/treat GVHD should be recorded at every  visit through 
Week 48post-transplant (Visit 17).  During the follow -up period through Week 48, 
concomitant medication review and recording of data is outlined in data entry  guidelines .
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization .  Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different participants. 
  05DKLV
080V09
PRODUCT: MK-8228 56
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a treatment
/randomization number .  The treatment /randomization number identifies the participant fo r 
all procedures occurring after treatment allocation /randomization .  Once a treatment 
/randomization number is assigned to a participant, it can never be re -assigned to another 
participant.
A single participant cannot be assigned more than 1 treatment /ra ndomization number.
8.1.8 Study Intervention Administrati on
The first dose of stud y intervention will be administered at the stud y site at Visit 2 (Day 1; 
~Week 14 post -transplant ). Subsequent dosing will be performed once daily b y the 
participant (ie, unsupervised at his/her home) at approximately  the same time each day .
For participants who develop a condition that interfere swith their ability  to swallow, or a 
condition that interferes with the absorption of the oral formulation (eg ,vomiting, diarrhea, 
or a malabsorptive condition) , aLET IV formulation is available for those participants 
randomized to L ET and IV placebo (saline or 5% dextrose) would be administered to those 
randomized to placebo.  IV administration is for short -course administration (up to 
approximately  4weeks) .  The study  pharmacist will be responsible solely  for the preparation 
of the IV study  medication .  Site personnel will administer t he IV study  medication through a 
sterile 0.2 -micron or 0.22 -micron p olyethersulfone ( PES) in- linefilter , usingonlyIV bags 
and infusion set materials that are diethylhexylphthalate (DEHP )-free. Refer to the
Pharmacy  Manual document for further details.
8.1.8.1 Timing of Dose Administration
Study  therapy should be administered/ taken at the same time each day .  Tablets are to be 
swallowed whole (ie, no crushing or chewing the tablet is allowed) .  Study  therapy  may  be 
administered with or without food (please refer to Section 5.3.1 for food restrictions 
applicable to those partici pants who are taking concomitant CsA) . 
If a participant misses a dose, the missed dose should be given as soon as possible during the 
same day .  If more than 18 hours have gone b y after the regular dosing time , then the missed 
dose should be skipped, and the normal dosing schedule should be resumed.  The next dose 
should not be doubled in order to “make up” what has been missed .  
If a participant vomits within 2hours of an oral administration, the full oral dose can be 
repeated one time within 6 hours after vomiting .  If a participant vomits and it has been 
longer than 2 hours from the time of oral administration, the dose should not be repeated.  
Take the next dose at the usual time. 
  05DKLV
080V09
PRODUCT: MK-8228 57
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.1.9 Discontinuation and Withdrawal
Participants who discontinue study  intervention prior to completion of the treatment period
should be encouraged to continue to be followed for all remaining study visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the Early Discont inuation Visit should be performed (at the time of 
withdrawal). An y AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4 and Visit Requirements as 
outlined in Section 1.3 (S oA)
.
8.1.10 Participant Blinding/Unblindi ng
STUDY MEDICATION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT .  EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify  the intervention used by a participant a nd /or the
dosage administered , he/she will contact the emergency  unblinding call center by  telephone 
and make a request for emergency  unblind ing.  A s requested b y the investigator or medically
qualified designee, the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor .  Prior to contacting the emergency  
unblinding call center to request unblinding of a participant’s intervention assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity  of the AEs observed, the relation to study  medication , the reason thereof, etc, in the 
medi cal chart .  If it is not possible to record this assessment in the chart prior to the 
unblinding, the unblinding should not be delayed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person perform ing the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.
Participants whose treatment assignment has been unblinded by the investigator or medicall y 
qualified designee and/or nonstudy  treating physician should continue to be monitored in the 
study .
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition .  In the event that the 
emergency  unblin ding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
participant safety .
8.1.11 Domicili ng
Not applicable . 
  05DKLV
080V09
PRODUCT: MK-8228 58
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.1.12 Calibration of Equipme nt
The investigator or qual ified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
8.2 Efficacy Assessmen ts
8.2.1 CMV DNA PCR Testing
Protocol -specified CMV DNA levels will be drawn at prespecified clinical visits and the 
CMV Infection Visitas indicated in the Study  SoA (Section 1.3) and sent to the central 
laboratory where CMV DNA PCR testing will be performed using a quantitative CMV 
DNA PCR assay  at the central laboratory   In this study , CMV DNA levels may be monitored 
using local laboratory  results for the clinical management of participants any time during the 
study . It is MANDATORY , however, to collect and send a confirmatory  plasma sample for 
CMV DNA PCR testing to the central laboratory  immediately prior to (ie, on the day  of) 
initiating PET or treatment for confirmed or suspected CMV disease (CMV infection visit ).  
(Note:   for a nysite in Japan where a positive local pp65 antigen test is used to drive the 
decision to initiate anti -CMV therap y, in addition to a confirmatory CMV DNA PCR testing, 
a blood sample must be collected for confirmatory local pp65 antigen testing prior to 
initiating PET ; the confirmatory  test results are not require d for initiating PET .)
In the event test results from the central laboratory are not available within the time frame the 
investigator wishes to initiate anti -CMV therap y(including PET) , the investigator may  use a 
positive local laboratory  test (CMV DNA PC R or pp65 antigen onl y) result in order to make 
the decision.  However, as described above, a confirmatory  plasma samples for CMV DNA 
PCR testing must also be sent to the central laboratory  prior to initiating PET.  The local 
laboratory  result must also be reported in such instances.
In the event that the confirmatory  result obtained on the day  of anti-CMV treatment
(including PET) initiation is NOT available ( eg, sample is lost or mishandled by  the 
investigator site prior to shipment, or is inadequate upon receipt at the central laboratory), a 
subsequent sample must be obtained and sent to the central laboratory  within 48-72 hours
after initiation of anti -CMV treatment.   Sample collection, storage ,and shipment instructions 
for plasma samples will be provid ed in the operations/laboratory  manual.
Assessment of CMV Disease
CMV disease will be assessed at every  visit from screening through Week 48post-transplant .  
Diagnostic criteria for the evaluation of CMV infection are outlined in Appendix 7.  If CMV 
disease is suspected, site should perform the CMV Infection Visit instead of the scheduled 
visit assessments (see Section 1.3, Schedule of Activities).  The investigator will ensure that 
clinical information, radiology  results, and specimens for the appropr iate diagnostic tests  
  05DKLV
080V09
PRODUCT: MK-8228 59
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
(including, but not limited to, viral culture, histopathology, immunohistochemical anal ysis, in 
situ hy bridization, CMV DNA PCR) as outlined in Appendix 10.7 will b e collected.
8.2.2 CMV DNA Resistance Analysis
Sample collection, storage, a nd shipment instructions for plasma samples wil l be provided in 
the central laboratory  manual.
CMV DNA s equence a nalysis willbe performed on samples from participants who meet the 
criteria for clinicall y significant CMV infection.  Resistance to LET will beassessed by 
genot ypic anal ysis of the CMV terminase complex gene s (UL56 , UL89, and UL 51) in DNA 
extract edfrom plasma samples collected as indicated in the Schedule of Activities
(Section 1.3).All CMV resistance genoty ping samples with detectable CMV DNA will be 
analyzed bynext-generation sequencing technology  through an established contract 
laboratory  with validated protocols in place .  The resistance genoty ping assay  is validated for 
plasma samples containing 500copies/m Lor higher ofCMV DNA with a sensitivity  cutoff 
of 5% to detect minor variants .  Ifmultiple CMV -positive resistance samples are collected , 
the last on- therap y and follow -up samples will be prioritized for resistance analysis.  
Phenoty pic anal ysis may  be performed on any UL56, UL 89, or UL51 DNA sequences which 
encode amino acid substitutions that have not been previously  characterized for LET
susceptibility .
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided.  The total amount of blood/tissue to be drawn/collected over the course of the stud y 
(from pre -study  to post -study  visits), including approximate blood/tissue volumes 
drawn/collected by visit and by sample type per particip ant, can be found in Sect ion10.2 
(Appendix 2).
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
On Day 1 (post-transplant Week 14), a complete phy sical examination will be conducted by 
an investigator or medically  qualified designee (consistent with local requirements) as per 
institutional standard . 
After randomization (Day  1), the phy sical examination does not need to be performed at 
every  visit; a targeted physical examination sho uld be performed onl y if a participant has an y 
complaints.  The timing of physical examinations is indicated in the Study SoA (Section 1.3).
Height and weight will be measured and recorded per the SoA .   
  05DKLV
080V09
PRODUCT: MK-8228 60
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.3.2 Vital Signs
Vital signs will be assessed at the time points indicated in the SoA (Section 1.3) and will 
include the following assessments : 
Body temperature (oral preferred, see below) , heart raterespiratory  rate, and blood 
pressure will be assessed.   NOTE: Oral temperatures should be taken, but if oral is 
not possible, ty mpanic, rectal, temporal, or axillary  temperatures may  be taken. 
Blood pressure and heart rate measurements should be preceded b y at least 5 minutes 
of rest for the participant in a quiet setting without distractions.
8.3.3 Electrocardiograms
Single 12-lead electrocardiogram (ECG) will be obtained and reviewed b y an 
investigator or medicall y qualified designee (consistent with local requirements) as 
outlined in the SoA (see Section 1.3) using an ECG machine that automatically 
calculates the hea rt rate and measures PR, QRS, QT, and QTc intervals .  Participant s 
should be shaved (ifnecessary )for proper lead placement.  Participant s should be 
resting in a semi -recumbent position for at least 10 minutes prior to having ECG 
readings obtained.
8.3.4 Child -Pugh Score
The Child- Pugh score will be assessed as indicated in the Study  SoA (Section 1.3)according 
to Appendix 8.  At the screening visit, the clinical assessment and the central laboratory  
parameters (total bilirubin, albumin, and PT/INR) obtain ed at that visit will be used to 
calculate the Child -Pugh score.  Thereafter, at each scheduled assessment of the Child -Pugh 
score, the clinical assessment at the scheduled study  visit and the most recently  collected and
available local laboratory paramete rs (total bilirubin, albumin, and INR) obtained at the 
corresponding scheduled study  visit, or up to oneweek prior to the scheduled study  visit, wil l
be used to calculate the Child -Pugh score.  As stated in Section 7.1,a participant must be 
discontinued from study  treatment but continue to be monitored in the study  if the participant 
develops both moderate hepatic insufficiency  (Child -Pugh Class B) and moderate -to-severe 
renal insufficiency  (defined as CrCl <50 mL /min as calculated b y the Cockcroft -Gault 
equation; see Section 5 .2), or develops severe hepatic insufficiency (Child- Pugh Class C) . 
8.3.5 Clinical Safety Laboratory Assessments
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency .
The investigator or medically  qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record an y clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the  
  05DKLV
080V09
PRODUCT: MK-8228 61
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
underly ing disease, unless judged b y the investigator to be more severe than expected 
for the participant's condition.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA .
If laboratory  values from nonprotocol specified laboratory  assessments performed at
the institution’s local laboratory  require a change in study  participant management or 
are considered clinically  significant b y the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
Forany laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study or within 14daysafter the last dose of study  
intervention, every  attempt should be made to perform repeat assessments until the 
values return to normal or baseline or if a new baseline is established as determined 
by the investigator .
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evalu ating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  the participant 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3 .
The investigator, who is a qualified ph ysician, will assess events that me et the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and ot her reportable safety events that occur after the consent form is signed 
but before treatment allocation/randomization must be reported b y the investigator if the 
event cause sthe participant to be excluded from the study , or is the result of a protocol -
specified intervention, including but not limited to washout or discontinuation of usual 
therap y, diet, or a procedure. 
  05DKLV
080V09
PRODUCT: MK-8228 62
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
From the time of treatment allocation/randomization through 14 day s following cessation of 
treatment, all AEs, SAEs, and other reportable safety  events must be reported by  the 
investigator. Thereafter, only  SAEs considered to be drug -related or leading to death should 
be reported through Week 48 post -transplant .
Additionally , any SAE brought to the attention of an investigator at an y time ou tside of the 
time period specified in the previous paragraph must be reported immediately to the Sponsor 
if the event is considered drug -related.
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3.
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting 
Time Period:
Randomizatio
n/ Allocation 
through 14 
days after last 
dose of study 
medicationReporting Time 
Period:
From 14 days 
after last dose of 
study medication
until study 
completionTimeframe to 
Report Event 
and Follow -up 
Information to 
SPO NSOR:
Nonserious
Adverse Event 
(NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusionReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusionReport all Report only if:
-drug-related. OR
-SAEs leading to 
death, regardless 
of causality Within 24 hours 
of learning of 
event
Pregnancy/
Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously 
reported – Follow 
to 
completion/termi
nation; report 
outcomeWithin 24 hours 
of learning of 
event 
  05DKLV
080V09
PRODUCT: MK-8228 63
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting 
Time Period:
Randomizatio
n/ Allocation 
through 14 
days after last 
dose of study 
medicationReporting Time 
Period:
From 14 days 
after last dose of 
study medication
until study 
completionTimeframe to 
Report Event 
and Follow -up 
Information to 
SPO NSOR:
Event of Clinical 
Interest (require 
regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-Potential DILI
-Require 
regulatory 
reportingNot required Within 24 hours 
of learning of 
event
Event of Clinical 
Interest (Do not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-non-DILI 
ECIs and those 
not requiring 
regulatory 
reportingNot required Within 5 
calendar days of 
learning of 
event
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days of 
learning of 
event
Overdose Report all Not required Within 5 
calendar days of 
learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other repor table safet y events 
including pregnancy  and exposure during breastfeeding, events of clinical interest (ECI), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follo w-up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AEs that occur in 
randomized participants for outcome. Further information on follow -up procedures is given 
in Appendix 3. 
  05DKLV
080V09
PRODUCT: MK-8228 64
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  autho rities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for 
Good Clinical Practice [GCP] ).
Investigator safety  reports must be prepared for suspected unexpected serious adverse
reactions (SUSAR s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee), including the pregnancy of a male participant ’s female 
partner, that occurs during the stud y are reportab le to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable.
8.4.7 Events of Clinical Interest (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study include:
1.An elevated AST or ALT lab oratory value that is ≥3ULN and an ele vated total 
bilirubin lab oratory value that is ≥2ULN and, at the same time, an alkaline 
phosphatase laboratory  value that is <2 ULN, as determined b y wa y of protocol -
specified laboratory  testing or unscheduled laboratory  testing. * 
  05DKLV
080V09
PRODUCT: MK-8228 65
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
*Note: These criteria are based upon available regulatory guidance documents.  The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underl ying etiology.  The study  site guidance for 
assessment and foll ow-up of these criteria can be found in the Investigator Study  File 
Binder (or equivalent).
8.5 Treatment of Overdose
In this stud y, an overdose is any dose higher than two times the prescribed dose specified in 
Section 6.6(Dose Modification [Escalation/Titration/Other]).
Sponsor does not recommend specific treatment for an overdose. Overdose during the study  
will be a reportable safety event (see Section 8.4.1 and Appendix 3 for further details) .
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study .
8.7 Pharmacodynamics
PD parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
Future biomedical research samples will not be collected in this study .
8.9 Planned Genetic Analysis Sample Collection
Planned genetic a nalysis samples will not be evaluated in this study .
8.10 Biomarkers
CMV -specific T -cell responses will be measured using the QuantiFERON -CMV assay  
[Becke, S., et al 2010] [Goldner, T., et al 2011] at various time points through Week 48 
post-transplant using plasma samples.  The proportion of participants with positive 
QuantiFERON- CMV assay  results will be correlated with the inci dence of clinically  
significant CMV infection through Week 48post-transplant and asses sed as an exploratory  
endpoint.  The central laboratory  based QuantiFERO N-CMV assay  results will not be shared 
with the respective site investigators. 
  05DKLV
080V09
PRODUCT: MK-8228 66
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.11 Health Outcomes Assessment
All-cause mortalit y, all rehospitalizations and CMV -related rehospitalizations, GVHD, select 
opport unistic infections, IV  medication other than L ET use , and recurrent CMV infection
will be measured to assess healthcare resource utilization.  The data collected may  be used to 
conduct exploratory  economic anal yses.  Protocol -mandated procedures, tests, an d 
encounters are excluded.
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.12.1 Screening
Approximately  14daysprior to treatment allocation/randomization, potential participants 
will be evaluated to determine that they  fulfill the entry  requirements as set forth in 
Sections 5.1 and 5.2 . Screening procedures may  be repeated after consultation with the 
Sponsor.
Hum an immunodeficiency virus (HIV) antibody test results documented at any  time prior to 
screening of the participant will be acceptable; a copy  of this HIV report must be available .  
(See Exclusion Criterion #10 in Section 5.2).  If documentation of a previo us HIV test is not 
available, the HIV antibody  test must be conducted using the central or local laboratory .  
Hepatitis B and hepatitis C screening should only  be performed if not previously  documented 
within the last 6 months.  If hepatitis C virus antibo dy is positive, HCV RNA PCR results 
should be provided (or, if not available, HCV RNA PCR testing will be performed b y the 
central or local laboratory).
8.12.2 Treatment Period
Study  medication (LET/Placebo
) may  begin as early  as 14 weeks ± 1 week post-transplant .  
Study  medication will be dispensed every  2 weeks and continue through Week 28
(~200days) post-transplant.  The treatment period is through Week 28 post -transplant 
regardless of when stud y medication is discontinued. Study  visits will occur every  2weeks 
through Week 28(~200days) post-transplant .  
The Day  1 Visit (as shown in the SoA, Section 1.3) will be the day  the participant is 
randomized and study  medication is initiated.  Study  medication will continue for 14 weeks
through the End of Treatment Visit at Week 28(~200days)post-transplant .  
All procedures listed under the stud y visits in the SoA ( Section 1.3) will be performed at the 
corresponding visit.  After allocation, the ph ysical examination does not need to be 
performed at every  visit ; a targeted ph ysical exam should be performed only when clinicall y 
indicated. 
  05DKLV
080V09
PRODUCT: MK-8228 67
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.12.2.1 Day 1 Visit
Day 1 procedures/assessments listed on the SoA ( Section 1.3) must be performed prior to 
initiation of study  medication .
For female participants of childbearing poten tial, a urine or serum pregnancy  test will be 
performed at the site prior to the initiation of study  medication .  If the urine or serum 
pregnancy  test result is negative, the participant will be eligible for allocation and the 
remainder of the Day 1 testin g/procedures will be performed.  If the urine or serum 
pregnancy  result is positive, the participant must not be randomized.
8.12.2.2 Study Medication Administration
The site pharmacist or study  coordinator will contact the IRT at all dispensing visits for 
assignme nt of the study  medication to be administered.  Sites should not contact the IRT for 
study  medication administration until the participant has met all criteria for the study  and is 
ready to receive the first dose of study  medication on Day  1.
The first dose of study  medication (LET or placebo to LET) will be administered at the trial 
site with monitoring by  investigative site personnel at the Day  1 Visit (Visit 2; Week 14
post-transplant ).  For participant s who cannot swallow and/or have a cond ition that may  
interfere with the absorption of the oral formulation at or after randomization/Day  1, a LET 
IV formulation is available for those participants randomized to L ET and IV placebo (saline 
or 5% dextrose) would be administered to those randomize d to placebo.  Participants should 
be switched from the IV formulation back to oral study  therapy as soon as such participant s 
are able to swallow and/or the condition necessitating the use of the IV formulation resolves
and the appropriate oral study  drug suppl y ma y be obtained for the participant .  Use of the IV 
formulation should generally  be limited to 4 weeks or less in duration per participant . 
However, it will be left to the investigator’s discretion to continue IV administration beyond 
4 weeks, if the benefit/risk ratio supports continued administration.
Participant s who are not on CsA will receive LET 480mg QD or placebo to L ET QD given 
orally .  Participant s who are receiving concomitant CsA will receive oral formulation of LET 
240mg QD or placeb o to L ET QD .  Participants requiring IV formulation (LET or placebo 
to LET) who are not on CsA will receive 480mg IV QD(Section 6.1).  Participants requiring
theIV formulation of LET or placebo to LET who are on concomitant CsA will receive 
240mg QD of IV study  medication (ie,participants randomized to placebo who require IV 
administration will be able to receive IV administration of placebo ).
If CsA is initiated after starting study  medication , the next dose of the study  medication
should be decrea sed to 240 mg once daily.  If CsA is discontinued permanently or for the 
long term in a participant alread y receiving study  medication , the next dose of study  
medication should be increased to 480 mg once daily .  If CsA is temporarily withheld due to 
high levels detected by therapeutic blood monitoring, the dose o fstudy  medication need not 
be adjusted (see Section 6.6) .  
  05DKLV
080V09
PRODUCT: MK-8228 68
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
The participant will be trained in the use of the Study Medication Diary.  He/she will be 
instructed to enter the number of tablets of study medication taken during the study  treatment
period.  IV study  medication will be recorded b y the unblinded pharmacist or study personnel 
in the CRF .
8.12.3 Optional Nurse Visit andTelephone Visit (Weeks 32 and 36 Only)
A visiting nurse service may  be utiliz ed (if locally available and approved for use) atVisit 11 
(Week 32) and Visit 13 (Week 36) in coordination with an investigator CMV assessment b y 
phone.  If a visiting nurse service is utilized, the investigator phone call should occur on the 
same day  as the nurse visit, or as soon as possible.  Refer to the nursing manual for additional 
details.
8.12.4 Follow -upPeriod/Visits
As stated in Section 8.12.2, participants will receive study  medication for 14 weeks through 
Week 28(~200days) post-transplant .  After t he last day  of study  medication , participant s 
will be followed via study visits from Week 30to Week 48post-transplant .  These v isits will 
occur every  2 weeks from Week 30 to Week 40 and every  4 weeks from Week 40 to 
Week 48 and all procedures listed in t he SoA (Section 1.3) corresponding to the visits will be 
performed.  
All participants will continue to be assessed for CMV infection/ disease through Week 48
post-transplant and CMV DNA PCR should be tested at the central laboratory as per the SoA 
(Section 1.3).  
Adverse event monitoring should include the collection of all AEs while on study  medication
and for 14 day sfollowing completion of study  medication in all participants.  Thereafter, 
only drug -related SAEs and SAEs leading to death will be collected through Week 48
post-transplant .  
8.12.5 Discontinued Participants Continuing to be Monitored in the Study
8.12.5.1 Discontinuation of Study Medication due to CMV Infection
For participants who develop CS -CMVi through Week 28post-transplant , the partic ipant 
should have a CMV Infection Visit.  At this visit, study  medication should be discontinued 
(if applicable) and all procedures as outlined in the S chedule of Activities (Section 1.3), 
including collection of a blood sample, should be performed immedia tely prior tothe 
initiation PET or treatment of CMV disease.  Additionally , a repeat plasma sample for CMV 
viral resistance testing should be collected at the next scheduled visit after the CMV Infection
Visit (Section 8.2.2) .
Such participants will continue to be followed in the study (despite discontinuing study  
medication and initiating anti -CMV therap y) and complete all remaining study  visits 
(including all subsequent treatment period visits).  
  05DKLV
080V09
PRODUCT: MK-8228 69
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
8.12.5.2 Discontinuation for Reasons O ther Than CMV Infec tion
Study Medication Discontinuation
Participants who discontinue study  medication prior to the last scheduled treatment visit for 
reasons other than CS -CMVi will continue to be followed in the study and complete all 
remaining stud y visits regardless of when cessation of study  medication occur s.  All specified 
procedures will be completed for these participants through Week 28post-transplant during 
the treatment period ( with the exception of study  medication administration, and S tudy 
Medication D iaryreview); and through Week 48post-transplant in the follow -up period as 
outlined in the SoA ( Section 1.3).
Early Study Discontinuation
The Earl y Discontinuation Visit will also be performed for all participants who prematurely 
discontinue the study (ie, withdraw consent) prior to the Week 48post-transplant visit.  It is 
very important to ensure that all procedures, as outlined in the Study  SoA (Section s 1.3), are 
performed for such participants at this visit prior to discontinuing from the study .  Aplasm a 
sample for CMV DNA PCR testing should be collected at this visit.
8.12.6 Survival Status
Updated survival status may  be requested at an y time, both during stud y conduct or after 
study  completion, or after a subject discontinues from the study.  All participants or their 
contacts may  be contacted for their survival status.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study.  Changes 
to analy ses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental SAP (sSAP) and referenced in the Clinical Study  Report 
(CSR) for the study .  Post hoc exploratory  anal yses will be clearl y identified in the CSR .
9.1 Statistical Analysis Plan Summary
Key elements of the statist ical anal ysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2through 9.12. 
Study Design Overview A Phase 3 randomized, double -blind, placebo -controlled clinical trial to 
evaluate the safety and efficacy of letermovir (LET) p rophylaxis when 
extended from 100 days to 200 days post -transplant in cytomegalovirus 
(CMV) seropositive recipients (R+) of an allogeneic hematopoietic stem 
cell transplant (HSCT)
Treatm ent Assignment Approximately 216participants who have already receiv ed ~100 days of 
LET will be randomized in a 2:1 ratio with 1 44receiving LET prophylaxis
for an additional 100 days (200 -dayarm) and72receiving placebo (100 -day 
arm).Treatment allocation / randomization will be stratified by study center 
and haploidentical donor (yes/no ). 
  05DKLV
080V09
PRODUCT: MK-8228 70
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Analysis Populations Efficacy: Full Analysis Set (FAS)
Safety: All Participants as Treated (APaT)
Prim ary Endpoint(s) Proportion of participants with clinically significant CMV infection from
Week 14 (~100 days) post-transplant through Week 28(~200days)
post-transplant
Key Secondary Endpoints 1.Safety and tolerability of LET 
2.Proportion of participants with clinically significant CMV infection 
from Week 14 post-transplant through Week 38post-transplant and 
from Week 14 post-transplant through Week 48post-transplant
3.Time to clinically significant CMV infection from Week 14 
post-transplant through Week 28 post-transplant andfrom Week 14 
post-transplant through Week 48 post-transplant
4.Proportion of partic ipants with PET for documented CMV viremia
from Week 14 post-transplant through Week 28post-transplant and 
from Week 14 post-transplant through Week 48 post-transplant
5.Proportion of participants with of all -cause mortality from Week 14 
post-transplant through Week 28post-transplant and from Week 14 
post-transplant through Week 48post-transplant
6.Time to all- cause mortality from Week 14 post-transplant through
Week 28post-transplant andfrom Week 14 post-transplant through
Week 48post-transplant
Statistical Methods for 
Key 
Efficacy/Immunogenicity/ 
Pharm acokinetic AnalysesThe primary hypothesis wi ll be evaluated by comparing LET to placebo with
respect to the proportion of participants wit hclinically significant CMV 
infection from Week 14 post-transplant through Week 28 post- transplant
using the stratified Mantel -Haen szel method [Koch, G. G., et al 1990] when 
LET prophylaxis is extended from 100 to 200days post-transplant .
Statistical Methods for 
Key Safety Analyses95% CIs (Tier 2 endpoints) w ill be provided for betw een-treatm ent 
differences in the percentage of participants with events; these analyses will 
be performed using th e Miettinen and Nurminen method [Miettinen, O. and 
Nurminen, M. 1985] .
Interim Analyses Periodic safety analyses will be conducted for the accruing data and
will be reviewed by an external Data Monitoring Committee (DMC) at 
regular intervals as outlined in the DMC charter. This will supplement 
routine in -house medical monitoring. No formal interim analyses for 
efficacy are planned for this study. However, efficacy data will be included 
as part of the periodic safety reviews when at least 40% of the participants 
have completed treatment or discontinued prior to completing treatment to 
allow  for an assessment of benefit -risk.
Multiplicity No formal efficacy analyses will be provided and there is no intention of 
stopping the trial due to overwhelming efficacy at any of these safety
reviews. Nevertheless, since unblinded efficacy data are being periodically 
reviewed, using a Haybittle -Peto α spending approach ,a small amount of 
alpha (α = 0.0001) will be allocated for each of these looks before testing 
the primary efficacy hypothesis at Week 28post-transplant . An allowance 
will be made such that a total of up to three of these unblinded efficacy 
reports may be presented at these periodic safety reviews. The final analysis 
can still be tested at 2.5% level without inflating Type -I error. 
  05DKLV
080V09
PRODUCT: MK-8228 71
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Sample Size and Power The planned sample size is 216. For the proportion of participants with 
clinically significant CMV infection from Week 14 post-transplant through 
Week 28 post-transplant ,the study has 80% pow er at an overall one -sided 
2.5% alpha -level to demonstrate that LET is superior to placebo in the 
prevention of clinically significant CMV infection when LET prophylaxis is 
extended from 100 to 200days post-transplant, iftheincidence rates of CS -
CMVi are8% for LET (200 -day arm) and 2 2% for placebo (100 -day arm).
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .  This study  will be conducted as a double -
blind study  under in -house blinding procedures.  The official, final database will not be 
unblinded until medical/scientific review has been performed, protocol deviations have been 
identified, and data have been declared final and complete.
The Clinical Biostatistics department will generate the randomized allocation schedule for 
study  treatment assignment .  Randomization will be implemented in the IRT.
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypoth eses/Estimation
Objectives of the stud y are stated in Section 3.
9.4 Analysis Endpoints
Efficacy  and safety endpoints that will be evaluated for within -and/or between -treatment 
differences are listed below, followed b y the descriptions of the derivations of selected 
endpoints.
9.4.1 Efficacy/Immunogenicity/Pharmacokinetics Endpoints
9.4.1.1 Efficacy Endpoints
An initial description of efficacy  measures is provided in Section 4.2.1.1 .
The primary  efficacy  endpoint will be the proportion of participants with clinically  
significant CMV infection from Week 14 (~100 days)post-transplant through Week 28 
(~200days)post-transplant, defined as the occurrence of either one of the following 
outcomes: 
onset of CMV end -organ disease (proven or probable)
OR
initiation of anti -CMV PET with approved anti -CMV agents (ganciclovir, 
valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and 
the clinical condition of the participant 
  05DKLV
080V09
PRODUCT: MK-8228 72
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
CMV end -organ disease will be determined using the definitions in Appendix 7 and 
confirmed b y an independent, blinded C AC.  The adjudication of cases b y the CAC (ie, the 
final CAC assessment) will take precedence over the investigator’s assessment for the 
purpose of anal ysis.  Only  the CAC -confirmed (proven or probable) cases of CMV end-o rgan 
disease will be included in the CMV end -organ disease category .  However, investigator -
assessed C MV end- organ disease cases that were not confirmed b y the CAC but in whom 
anti-CMV therap y was initiated (in the setting of documented CMV viremia at a ce ntral 
laboratory ) will be included in the initiation of PET category and, therefore, qualify as having 
clinically  significant CMV infection .  Concordance/discordance between CAC and 
investigator assessment will be summarized.
Documented viremia is defined as any  quantifiable CMV viral DNA on a confirmatory  
sample obtained immediately  prior to (ie, on the day  of) the initiation of treatment for CMV 
disease or PET, as measured b y the Roche COBAS®AmpliPrep/COBAS TaqMan®
(CAP/CTM) Sy stem in the central laborat ory.  In the event that the confirmatory  result is not 
available, a subsequent central laboratory  result collected from a sample obtained within 
7dayswill be used.  Initiation of anti- CMV therapy  without documented CMV viremia 
(using the central laboratory ) will not be considered as a case for clinicall y significant CMV 
infection.  Similarly , quantifiable CMV viral DNA alone without initiation of anti -CMV 
therap y will not be considered as a case for clinically significant CMV infection .
  If there are 
cases where anti -CMV therapy is initiated with no quantifiable CMV viral DNA using the 
central laboratory  data, a sensitivity  anal ysis will be provided using the local laboratory  
results.
The secondary  efficacy  endpoints are: 
1.Proportion of participants wi th clinically  significant CMV infection from Week 14 
post-transplant through Week 38post-transplant and from Week 14 post -transplant
Week 48post-transplant .  This endpoint will use the same definition of clinically  
significant CMV infection as in the pri mary  efficacy  endpoint.
2.Time to onset of clinically significant CMV infection from Week 14 post -transplant
through Week 28post-transplant and from Week 14 post -transplant through Week 48 
post-transplant . 
The time to onset of clinically significant CMV infection will be calculated in days, 
from the day  of transplant to the day  of onset of CMV end -organ disease or to the day  
of initiation of anti- CMV PET.  For cases where CMV end -organ disease is 
confirmed b y the CAC, date of the first diagnostic test (including, but not limited to, 
radiology  tests, viral culture, histopathology ,immunohistochemical anal ysis, in situ 
hybridization, and CMV DNA PCR) will be identified by the CAC as part of their 
medical review and used as the time of onset of CMV end -organ disease .  For cases 
where anti -CMV PET is initiated in the setting of documented viremia (including 
those applicable cases where CMV end -organ disease was not confirmed by the 
CAC), the start date of anti -CMV therap y will be used .  If both criteria for clinically  
significant CMV infection are met, the time to onset will be calculated from the day 
of transplant to the earlier day  on which one of the criteria is met.   
  05DKLV
080V09
PRODUCT: MK-8228 73
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
3. Proportion of participants with initiation of P ET for documented CMV viremia from 
Week 14 post -transplant through Week 28post-transplant ,and from Week 14 
post-transplant through Week 48post-transplant .This endpoint will use the same 
definition for initiation of PET for documented CMV viremia as in the primary 
efficacy  endpoint.
4.Proportion of participants with all-cause mortalit yfrom Week 14 post -transplant
through post-Week 28post-transplant ,and from Week 14 post -transplant through 
Week 48post-transplant .
5.Time to all-cause mortality from Week 14 post -transplant through Week 28 
post-transplant ,and from Week 14 post -transplant through Week 48 post -transplant . 
The time to all -cause mortality  will be calculated in days, from the day  of transplant 
to the day of death. 
9.4.2 Safety Endpoints
An initial description of safety measures is provided in Sections 8.3and 8.4. 
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs, laboratory  values and vital sign s.  All AEs will be collected through 14 daysafter 
completion of treatment period.  Thereafter, all drug-related SAEs and SAEs leading to death 
will be collected through Week 48post-transplant .   
9.4.3 Exploratory Endpoints
1. Proportion of participants with CMV end -organ disease from Week 14 post -trans plant
through Week 28 post -transplant ,andfrom Week 14 post -transplant through Week 48 
post-transplant
2.Time to CMV end -organ disease from Week 14 post -transplant through Week 28 
post-transplant , and from Week 14 post -transplant through Week 48 post -transplant . 
The time to CMV end -organ disease will be calculated in days, from the day  of 
transplant to the day of CMV end -organ disease .
3.Proportion of participants with documented CMV viremia ≥300 copies/mL from 
Week 14 post -transplant through Week 28 post -transplant ,and from Week 14 
post-transplant through Week 48 post -transplant .
4. The time to documented CMV viremia ≥300 copies/mL from Week 14 
post-transplant through Week 48 post -transplant .
5. Proportion of participants with select opportunistic infections other than CMV 
infection from Week 14 post-transplant through Week 28 post -transplant ,andfrom 
Week 14 post -transplant through Week 48 post -transplant . 
  05DKLV
080V09
PRODUCT: MK-8228 74
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
6.Proportion of participants with GVHD from Week 14 post -transplant through 
Week 28 post -transplant ,and from Week 14 post -transplant through Week 48 
post-transplant .
7.Proportion of participants with all re hospitalizations and re hospitalizations for CMV 
infection/ end-organ disease from Week 14 post -transplant through Week 28 
post-transplant ,and from Week 14 post -transplant through Week 48 post -transplant .
8.Days on intravenous medications other than LET from Week 14 post -transplant
through Week 28 post -transplant ,and from Week 14 post -transplant through Week 48 
post-transplant .
9.Proportion of participants with recurrent CMV infection from Week 14 
post-transplant through Week 28 post -transplant ,and from Week 14 post -transplant
through Week 48 post -transplant .
10.Proportion of participants with CMV- specific T cell responses (positive,
indeterminate, or negativ e) as measured b y the release of γ -interferon using the
QuantiFERON- CMV assa y.
11.Antiviral resistance to LET in prophylaxis failures.
9.5 Analysis Populations
9.5.1 Efficacy Analysis Populations
The Full Anal ysis Set (FAS) population will serve as the primary population for the analy sis 
of efficacy  data in this study .  The FAS population consists of all randomized participants 
who received at least one dose of study  treatment.
9.5.2 Safety Analysis Populations
Safety Anal yses will be conducted in the All Participant s as Treated (APaT) population, 
which consists of all randomized participants who received at least one dose of study 
treatment .  Participants will be included in the treatment group corresponding to the stud y 
treatment they  actually  received for the analy sis of safet y data using the APaT population.  
This will be the treatment group to which they are randomized except for p articipants who 
take incorrect stud y treatment for the entire treatment period; such participants will be 
included in the treatment gro up corresponding to the study  treatment actually  received.  
At least one laboratory orvital sign measurement obtained subsequent to at least one dose of 
study  treatment is required for inclusion in the analy sis of the respective safety  parameter.  
To ass ess change from baseline, a baseline measurement is also required. 
  05DKLV
080V09
PRODUCT: MK-8228 75
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
9.6 Statistical Methods
Statistical testing and inference for safet y analyses are described in Section 9.6.2. Efficacy  
results that will be deemed to be statistically  significant after consi deration of the Ty peI 
error control strategy  are described in Section 9.8. Nominal p -values may  be computed for 
other efficacy  anal yses but should be interpreted with caution due to potential issues of 
multiplicity , sample size, etc.  Unless otherwise sta ted, all statistical tests will be conducted 
at the α=0.02 5 (1-sided) level.
9.6.1 Statistical Methods for Efficacy Analyses
This section describes the statistical methods that address the primary and secondary 
objectives.  Methods related to exploratory endpoints will be described in the supplemental 
SAP.
Missing Data Handling
There are three t ypes of missing values:
Intermittent missing values due to a missed or skipped visit.  
Monotone (non -intermittent) missing due to premature discontinuation from th e 
study : viremia at study discontinuation .
Monotone missing due to premature discontinuation from the study :no viremia at 
study discontinuation.
Table 4provides a summary  of approaches to handle missing values.
Table 4 Summary  of Approaches to Handle Missing Values
Approach Intermittent MissingMonotone Missing 
No Viremia at Study 
DiscontinuationViremia at Study 
Discontinuation
OF No failure No failure Failure
NC=F Failure Failure Failure
DAO Excluded Excluded Excluded
F = failure; NC = Non -Com pleter; OF = Observed Failure; DAO = Data -As-Observed 
  05DKLV
080V09
PRODUCT: MK-8228 76
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
The primary  missing data approach will be the Observed Failure (OF) approach in order to 
obtain an estimate of the proportion of clinicall y significant CMV infection in participants 
who receive proph ylaxis study  treatment .  Using this approach, participants who develop 
clinically  significant CMV infection or participants who disco ntinue prematurely  from the 
study  with viremi awill be counted as failures ,and participants who discontinue prematurely  
from the study  for an y reason without viremi aor those who are missing data at the time
points of interest are not considered failures.  Imputing all participants who discontinue from 
the study  prematurel y without viremia as failures is likely  to substantially  overest imate the 
proportion of participants with clinically significant CMV infection.
Two secondary  missing data approaches will be used for supportive anal yses.  The first is the 
Data -As-Observed (DAO) approach .  Inthe DAO approach, an y participant with missing 
value for a particular endpoint , either because they discontinued from the study without the 
endpoint or are missing data at the key  time point (eg ,missed visit, missing lab value), will 
be excluded from the analy sis.  The second approach is the Non -Completer = Failure (NC=F) 
approach , which provides the worse -case scenario estimate of the proportion of clinically  
significa nt CMV infection.  Non- completers refer to participants who prematurel y 
discontinue from the study for an y reason without having developed CMV infection or 
participants who are missing data at the time points of interest . These participants will be 
considered failures using the NC=F approach.
Primary  Efficacy  Anal ysis
To test the primary  hypothesis that LET is superior to placebo in the prevention of clinically 
significant CMV infection when LET proph ylaxis is extended from 100 to 200days
post-transplant , the stratum -adjusted Mantel -Haenszel method (with continuity  correction)
will be used to compare the proportion of subjects with clinically  significant CMV infection
from Week 14 (~100 days) post-transplant through Week 28(~200days)post-transpla nt
between the two treatment groups [Koch, G. G., et al 1990] .  The s tratification factor of
haploidentical donor (yes/no) will be included in the primary  efficacy  analy sis.  Cochran 
Mantel- Haenszel weights will be used to calculate the overall between- group differences 
across strata .  LET is concluded superior to placebo if 1-sided p- value is less than or equal to 
0.0249 ( see Section 9.8 for alpha adjustment) .  Due to the anticipated large number of study  
center s, study  center will not be included as a stratification factor in the primary efficacy 
analysis but may  be explored as a sensitivity  analy sis.  The primary  efficacy  anal ysis will be 
performed on the FAS population.  A sensitivity  analy sis excluding those subjects who had 
quantifiable CMV viral DNA on Day  1 will be provided. The primary  missing data approach 
will be the OFapproach ; supportive anal yses usin g different missing data approaches will 
also be conducted (see Table 5).
Two a dditional sensitivity anal yses for the primary endpoint will be performed to assess 
1)the proportion of participants with either CMV disease or PET initiatio n based on CMV 
viremia ≥ 300 copies/mL (ie ,participants who initiated PET without meeting the threshold 
will not be considered a case of CS-CMVi), and 2) the proportion of participants with either 
CMV disease or CMV viremia of ≥300 copies/mL regardless of whether PET was initiated. 
  05DKLV
080V09
PRODUCT: MK-8228 77
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Since t he use of a therapy  with anti -CMV activity may  confound the results of this study , an 
additional sensitivity  analy sis will be conducted in which p articipants who start a therap y 
with anti -CMV activity  will be censored at the time they  begin such therapy .  Subjects with 
CS-CMVi prior to taking a therap y with anti -CMV activity  will be classified as having 
CS-CMVi.  Those who did not have CS -CMVi prior to taking a therap y with anti -CMV 
activity  (including subjects who subsequ ently  develop CS -CMVi) will be classified as not 
having CS -CMVi and censored at the time they  started taking the anti -CMV therapy . 
Secondary  Efficacy  Analy ses
To assess the difference in the proportion of participants with the following secondary  
endpoint s: 
clinically  significant CMV infection from Week 14 post-transplant through Week 38
post-transplant
clinically  significant CMV infection from Week 14 post-transplant through Week 48
post-transplant
initiation of P ET for documented CMV viremia from Week 14 post -transplant
through Week 28post-transplant
initiation of P ET for documented CMV viremia from Week 14 post -transplant
through Week 48post-transplant
all-cause mortality  from Week 14 post -transplant through Week 28post-transplant
all-cause mortality  from Week 14 post -transplant through Week 48post-transplant
Similar to the primary  endpoint ,95% confidence interval for the difference in proportion 
between treatment groups will be calculated using the stratum -adjusted Mantel -Haenszel 
method with stratification by  haploidentical donor (yes/no) [Koch, G. G., et al 1990] .  A 
nominal p- value will be provided to assess the strength of evidence of the effect.
Time to onset of clinically significant CMV infection from Week 14 post -transplant through 
28weeks post-transplant and from Week 14 post -transplant through Week 48 post -transplant
will be estimated using the nonparametric Kaplan -Meier method.  The Kaplan -Meier curve 
will be plotted by  treatment arm and a nominal p-value for the between- arm difference in 
time to onset of clinically significant CMV infection will be provided using the stratified log-
rank test stratified b y haploidentical donor (yes/no ).Observations will be censored at last 
assessment . Time to all -cause mortalit y from Week 14 post -transplant through 28 weeks
post-transplant and from Week 14 post -transplant through Week 48 post -transplant will be 
estimated similarly . 
  05DKLV
080V09
PRODUCT: MK-8228 78
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table 5 Analy sis Strategy  for Key  Efficacy  Variables
Endpoint/Variable
(Description, Time Point)Primary 
vs. 
Supportive 
Approach† Statistical MethodAnalysis 
PopulationMissing Data 
Approach*
Prim ary Endpoint
Proportion of participants with clinically 
significant CMV infection from Week 14 
post-transplant through Week 28 
post-transplantP Stratified M&H‡FAS OF
S Stratified M&H‡FAS DAO 
S Stratified M&H‡FAS NC=F
Secondary Endpoints
Proportion of participants with clinically 
significant CMV infection from Week 14 
post-transplant through Week 38 
post-transplant and from Week 14 
post-transplant through Week 48
post-transplantP Stratified M&H‡FAS OF
S Stratified M&H‡FAS DAO
S Stratified M&H‡FAS NC=F
Time to onset of clinically significant CMV 
infection from Week 14 post-transplant
through Week 28 post-transplant ,and 
from Week 14 post-transplant through 
Week 48 post-transplantP Kaplan -Meier FAS Censored at last 
assessment
Proportion of participants with initiation of 
anti-CMV PET for CMV viremia from 
Week 14 post-transplant through Week 28 
post-transplant ,andfrom Week 14 
post-transplant through Week 48 
post-transplant weeksP Stratified M&H‡FAS OF
S Stratified M&H‡FAS DAO
S Stratified M&H‡FAS NC=F
Proportion of participants with all -cause 
mortality from Week 14 post-transplant
through Week 28 post-transplant ,and 
from Week 14 post-transplant through 
Week 48 post-transplant weeksP Stratified M&H‡FAS OF
Time to all- cause mortality from Week 14 
post-transplant through Week 28 
post-transplant ,andfrom Week 14 
post-transplant through Week 48 
post-transplantP Kaplan -Meier FAS Censored at last 
assessment
  †P=Primary approach; S=Supportive approach.
  ‡Stratum -adjusted Mantel -Haenszel method with stratification by haploidentical donor (yes/no)   
*  OF=observed failure; DAO=data -as-observed ;NC=F = non -completers equal failure  
  05DKLV
080V09
PRODUCT: MK-8228 79
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
9.6.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs, laboratory  tests, and vital signs measurements.
The anal ysis of safet y results will follow a tiered approach ( Table 6).  The tiers differ with 
respect to the anal yses that will be performed.  Adverse events (specific terms as well as 
system organ class terms) and events that meet predefined limits of change (PDL Cs) in 
laboratory , and 
vital signs parameters are either pre specified as “Tier 1” endpoints, or will be 
classified as belonging to “Tier 2 ”or “Tier 3 ”based on the observed proportions of 
participants with an event.  
Safety  parameters or AEs of special interest that are identified a priori constitute “Tier 1” 
safety endpoints that will be subject to inferential testing for statistical significance.  There 
are no Tier 1 events for this protocol as LEThas not been associated with any  significant 
AEsthat need to be characterized compared to placebo .  
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% confidence intervals 
provided for differences in the proportion of participants with events ( Miett inen and 
Nurminen [ M&N ]method) [Miettinen, O. and Nurminen, M. 1985] .
Membership in Tier 2 requires that at least 8participants in the 200- dayarmor 2participants 
in the 100-dayarmexhibit the event; all other AEs and predefined limits of change will 
belong to Tier 3.
The thresholds of events were chosen because the 95% confidence interval for the between -
group difference in percent incidence will always include zero when fewer participants per 
group, respectively , experience events and thus would add little to the inte rpretation of 
potentially  meaningful differences.  Because man y 95% confidence intervals may be 
provided without adjustment for multiplicity , the confidence intervals should be regarded as 
a helpful descriptive measure to be used in review, not a formal me thod for assessing the 
statistical significance of the between -group differences in AEs and safety  parameters that 
meet predefined limits of change.
In addition to individual events that occur in 8 or more participants in the 200-day arm or 
2participants in the 100- day arm, the broad AE categories consisting of the proportion of 
participants with an y AE, a drug -related AE, a serious AE, an AE which is both drug -related 
and serious, and discontinuation due to an AE will be considered Tier 2 end points. 
Tier 3 Events
Safety  endpoints that are not Tier 1 or 2 events are considered Tier 3 events.  Only point 
estimates by  treatment group are provided for Tier 3 safet y parameters. 
  05DKLV
080V09
PRODUCT: MK-8228 80
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Continuous Safety Measures 
For continuous measures such as changes from baseline in laboratory and vital signs 
parameters, summary  statistics for baseline, on -treatment, and change from baseline values 
will be provided by  treatment group in table format.
Table 6 Analy sis Strategy for Safety  Parameters
Safety Tier Safety Endpoint95% CI for Treatment 
Com parisonDescriptive 
Statistics
Tier 2 Any AE†X X
Any Serious AE X X
Any Drug -Related AE X X
Any Serious and Drug -Related AE X X
Discontinuation due to AE X X
Specific AEs, SOCs, or PDLCs‡(incidence 
≥8participants in the 200 -day arm or ≥2 
participants in the 100 -day arm)X X
Tier 3 Specific A Es, SOCs or PDLCs (incidence 
≥1participant in either arm)X
Change from Baseline Results (Labs, Vital Signs) X
95% CIs will be based on the method of Miettinen and Nurminen (1985).
†Indicates broad AE category of the number of participants reporting any adverse event
Note: AE=adverse event; CI =confidence interval; SOC=System Organ Class; PDLC=Pre -Defined Limit of Change; 
X =results will be provided .
9.7 Interim Analyses
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses.  Blinding to 
treatment assignment will be maintained at all investigational sites.  The results of interim 
analyses will not be shared with the investigators prior to the complet ion of the study .  
To supplement the routine safet y monitoring outlined in this protocol, an external D MCwill 
serve as the primary  reviewer of the results of the interim analy ses of the study  and will make 
recommendations for discontinuation of the study or protocol modifications to the EOC (see 
Appendix 1; Section 10.1.4 [Committees Structure –Executive Oversight Committee ]).  No 
formal interim anal yses for efficacy  are planned for this study .  However, to allow for an 
assessment of benefit -risk, efficacy  data willbe included as part of the periodic safet y
revie wswhen at least 40% of the participants have completed treatment or discontinued prior 
to completing treatment .  The DMC will monitor the trial with suggested periodic reviews 
occur ringapproximately  every  6months.  If the DMC recommends modifications to the 
design of the protocol or discontinuation of the study, this EOC may be unblinded to results 
at the treatment level in order to act on these recommendations.  The extent to which  
  05DKLV
080V09
PRODUCT: MK-8228 81
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
indiv iduals are unblinded with respect to results of interim analyses will be documented b y 
the unblinded statistician.  Additional logistical details will be provided in the DMC charter .  
Treatment -level results from the interim analy sis will be provided to the DMC by the 
unblinded statistician.  Prior to final study  unblinding, the unblinded statistician will not be 
involved in any  discussions regarding modifications to the protocol, statistical methods, 
identification of protocol deviations, or data validati on efforts after the interim analyses.
9.8 Multiplicity
The DMC will be provided with unblinded descriptive summaries of the efficacy data at their 
periodic safety  reviews when at least 40% of the participants have completed treatment or 
discontinued prior to completing treatment for an assessment of benefit -risk.  No formal 
efficacy  anal yses will be provided and there is no intention of stopping the trial due to 
overwhelming efficacy  at any  of these safet y reviews .  Nevertheless, since unblinded efficacy  
data are being periodically reviewed, using a Hay bittle -Peto α -spending approach ,a small 
amount of alpha (α = 0.0001) will be allocated for each of these looks before testing the 
primary  efficacy  hypothesis at Week 28post-transplan t.  An allowance will be mad e such 
that a total of up to three of these unblinded efficacy reports may be presented at these 
periodic safety  reviews .  The final analy sis can still be tested at 2.5% level without inflating 
Type-I error.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size a nd Power for Efficacy Analysis
Data from P001 in participants who were in the high-risk stratum as defined in P001 were 
used to estimate the clinically  significant CMV infection ratesfor this study ,since these 
populations are similar between the two studies.  The 100-day arm in this study  is similar to 
those in the high- risk stratum on LET who completed treatment without any  clinically  
significant CMV infection in P001, in which 20.5% had clinicall y signi ficant CMV infection
after completing treatment and through Week 24 post-transplant .  This would be expected to 
be slightly  higher through Week 28 post -transplant leading to an estimate of 22% for through 
Week 28post-transplant in this study .  The event r ate for the 200 -day arm is expect ed to be 
similar to the event rate at the end of LET treatment at Week 14post-transplant for
participants in the P001 -defined high- risk stratum , which was 10.8% (11/102, including 
4participants who had discontinued LETdue to AEs and then developed CS-CMVi).  Since 
this study  will enroll participants who will have already  tolerate d LET for 100 day s, it is 
expected that a lower percentage of patients will discontinue treatment due to AEs, thus 
lowering the overall failur e rate in the 200 -day arm to ~8%.
This study will randomize a total of 216 participants (in a 2:1 ratio) with 144in the LET
(200-day) arm and 72 in the placebo (100 -day) arm which will have 80% power at an overall 
one-sided, 2.5% alpha -level, todemonstrate the primary  hypothesis that extending LET 
prophy laxis to 200dayspost-transplant is superior to 100 day s of LET prophy laxis 
post-transplant in the prevention of clinically  significant CMV infection .  This assumes 
incidence rates of CS -CMVi of 8% for LET (200 -day arm) and 22% for placebo (100 -day  
  05DKLV
080V09
PRODUCT: MK-8228 82
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
arm). The calculation is based on normal approximation by  Pearson Chi -square test for 
proportion difference without continuity correction and is carried out using (SAS v9.4). The 
minimum criterion for success is that the upper bound of 95% CI of difference <0. Given the 
assumed response rate in 200-day arm, this may  occur when the observed difference between 
treatment groups is approximately -10% or smaller .  Table 7presents the power under 
various assumptions of rates in the two arms using the OF approach for missing data .
Table 7 Power(%) Under Various Assumptions (With 144 Participant s Randomized in 
200-day Armand 72 in 100 -day Arm)
Rate in Placebo 
(100-d ay)ArmRate in LET (200-d ay)Arm
6 7 8 9 10 11
18 76 67 58 49 39 31
20 85 78 70 62 53 44
22 91 86 80 73 65 57
24 95 92 88 82 76 69
26 97 65 93 89 84 79
28 99 98 96 94 90 86
9.9.2 Sample Size and Power for Safety Analysis
The probability  of observing at least one of a particular AE in this study  depends on the 
number of participants treated and the underl ying percentage of participants with that AE in 
the study  population.  If the underl ying incidence of a parti cular AE is 1% (1 of every  
100participants receiving the drug), there is a 52% chance of observing at least one of that 
particular AE among 72 participants in the placebo ( 100-day)armor a 76% chance of 
observing at least one of that particular AE among 144participants in the LET ( 200-day)
arm.  If no AE of that particular ty pe are observed among the 144participants in the LET 
(200-day)arm,this study will provide 95% confidence that the underl ying percentage of 
participants with that particular AE is <2.5% (one in every  40participants).  
The estimate of and the upper bound of the 95% confidence interval for the underly ing 
percentage of participants with a particular AE given various h ypothetical observed number 
of participants with the AE are provided in Table 8.  The calculation is based on the exact 
binomial method proposed by  Clopper and Pearson (1934 ) [Clopper, C. J. and Pearson, E. S. 
1934] and is carried out using SAS v9.4. 
  05DKLV
080V09
PRODUCT: MK-8228 83
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table 8 Estimate of Incidence of AEs and 95% Upper Confidence Bound Based on
Hypothe tical Numbers of Participants with AEs
Hypothetical Number of Participants with 
an AE (Estimate of Incidence, %)95% Upper Confidence Bound†
N=720 (0) 5.0
2 (2.8 ) 9.7
4 (5.6 ) 13.6
6 (8.3 ) 17.3
N=1440 (0) 2.5
4 (2.8 ) 7.0
8 (5.6 ) 10.7
12 (8.3 ) 14.1
†Based on the tw o-sided exact confidence interval of a binomial proportion (Clopper and Pearson, 1934).
9.10 Subgroup Analyses
To assess the consistency of the treatment effect across various subgroups, the estimate of the 
between -arm treatment effect (with a nominal 95% CI) for the primary  efficacy  endpoint will 
be tabulated and plotted within each category  of the following classification variables:
Age category  (≤65 versus >65 y ears)
Sex (female, male)
Race ( white, black, Asian , other )
Systemic steroid exposure within 6 weeks prior to randomization (y es, no)
Donor t ype(mismatched related, m atched unrelated , mismatched unrelated)
Haploidentical donor (y es, no)
Cord blood (yes, no)
T-cell depleted grafts (yes, no)
Receipt of anti-thymocy te globul in (yes, no)
The consistency  of the treatment effect will be assessed descriptively  via summary  statistics 
by category  for the classification variables listed above .  Other clinically  relevant variables 
may be identified for which additional subgroup analy ses may  be performed.  Subgroup 
analyses will not be conducted in categories that have less than 10% of the participants in 
either LET or placebo group (ie,no estimate of treatment difference and confidence intervals 
will be provided ). 
  05DKLV
080V09
PRODUCT: MK-8228 84
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
9.11 Compliance (Medication Adherence)
Study  medication data for L ET (200-day arm) and placebo ( 100-day arm) will be collected 
during the stud y.  A day  within the study  will be considered an “On -Therapy ” day  if the 
participant takes at least 1dose.  For a participant who is followed for the entire study  period, 
the “Number of daysShould be on Therap y” is the total number of daysfrom randomization 
to the last scheduled day  for treatment administration for that participant.  For a participant 
who discontinued from the study medication, the “Number of daysShould be on Therap y” is 
the total number of daysfrom randomization to the date of the last dose of study  medication .
For each participant, percent compliance will then be calculated using the following formula:
Summar y statistics will be provided on percent compliance b y treatment group for the AP aT
population.
9.12 Extent of Exposure
The Extent of Exposure to study  treatment will be evaluated b y summary for the “Number 
ofdayson Therap y” by treatment group.
 
  05DKLV
080V09
PRODUCT: MK-8228 85
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10 SUPPORTING DO CUMENTATION AND OPER ATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet pro tocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budge tary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the tria l protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedu res, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues  
  05DKLV
080V09
PRODUCT: MK-8228 86
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the re commendations published by the Intern ational Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to protect participa nt safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All particip ation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulatory autho rities will have 
access to confidential medical records t hat might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics c ommittee.
IV. Finan cial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants. 
  05DKLV
080V09
PRODUCT: MK-8228 87
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsorin g 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with loca l guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disc losure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This ma y involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordan ce with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities. 
  05DKLV
080V09
PRODUCT: MK-8228 88
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affilia ted institution and employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of Particip ant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  signing the co nsent form, the participant agrees 
to this process. If stud y documents will be photocopied during the process of verifying 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transm ission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Inform ation
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
10.1.4.1 Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent pe er-reviewed 
scientific publications.
10.1.4.2 Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  the
DMC regarding the study. 
  05DKLV
080V09
PRODUCT: MK-8228 89
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.1.4.3 External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC m ust not be involved with the study  in an y other 
way (eg, they  cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the study. Also, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants ( Section 9.7) and 
recommend to the EOC whether the stud y should co ntinue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance stru cture; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
10.1.4.4 Clinical Adjudication Committee (CAC)   
A Clinical Adjudication Com mittee (CAC) will evaluate the following events for the 
purposes of confirming them according to the criteria in Section 9, as well as evaluating the 
presence of confounding factors.
The CAC will review clinical, virological, and histopathological data as well as the 
investigator’s assessment for adjudicating all potential cases of CMV end -organ disease.  
CMV end -organ disease will be determined using the definitions in Appendix 7
(Section 10.7).
All personnel involved in the adjudication process will remai n blinded to study  intervention
allocation throughout the study .
10.1.5 Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordanc e with 
standard editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity is not directed b y the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary  information and to provide comments.  
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements. 
  05DKLV
080V09
PRODUCT: MK-8228 90
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendment s Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www .clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clini cal trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information.
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated registries are that of the 
Sponsor and agrees n ot to submit any  information about this study or its results to those 
registries. 
10.1.7 Compliance with Law, Audit, and Debarmen
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with t his protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical inve stigations sponsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study  
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information fr om inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the reg ulatory  authority . 
Persons debarred from conducting or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened. 
  05DKLV
080V09
PRODUCT: MK-8228 91
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.1.8 Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically  signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by
 the investigator 
upon request and also shall be made available at the study  site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rig hts of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed I CF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention peri od without the written approval of the Sponsor. No records may  be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must b e explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available. 
  05DKLV
080V09
PRODUCT: MK-8228 92
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site par ticipation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC. 
  05DKLV
080V09
PRODUCT: MK-8228 93
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.2 Appendix 2: Clinical Laboratory Tests
Laboratory  tests are detailed in Table 9.
Local laboratory  results are only  required in the event that the central laboratory  
results are not available in time for either study  medication administration and/or 
response evaluation.  If a local sample is required, it is important that the sample for 
central anal ysis is obtained at the same tim e.  Additionally , if the local laboratory  
results are used to make either a study  medication decision or response evaluation, the 
results must be entered into the CRF.
Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5of the protocol.
Additional tests may  be performed at an y time during the study as determined 
necessary  by the investigator or required b y local regulations. 
  05DKLV
080V09
PRODUCT: MK-8228 94
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table 9 Laboratory  Assessments 
Laboratory 
AssessmentsParametersCentral LaboratoryHem atology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry Blood Urea 
Nitrogen 
(BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of 
normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose 
[Indicate if 
fasting, or 
nonfasting]Calcium Alkaline 
phosphatase
Other Tests CMV DNA Sequence Analysis to be performed only in participants 
who have both a clinically significant CMV infection and detectable 
CMV DNA 
CMV DNA PCR 
QuantiFERON -CMV
Tests Performed 
at ScreeningCoagulation:  PT/INR (using central laboratory at Screening ; local 
laboratory testing to be used at other visits)
Creatinine Clearance (calculated using the Cockcroft -Gault equation 
for participants )Central or Local 
LaboratoryRoutine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, and m icroscopic examination
Tests Performed 
at ScreeningSerum β human chorionic gonadotropin (β hCG) pregnancy test (for 
WOCBP)
Serology : HIV antibody, hepatitis B surface antigen (HBsAg ), and 
hepatitis C virus (HCV) antibody   
HCV RNA PCR:  to be done only in participants who test positive for 
HCV antibody 
  05DKLV
080V09
PRODUCT: MK-8228 95
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
The i nvestigator (or medically  qualified designee) must document their review of each 
laboratory  safet y report.
Laboratory /analyte results that could unblind the study  will not be reported to investigative 
sites or other blinded personnel until the study  has been unblinded.   The central laboratory  
based QuantiFERO N-CMV assay  results will not be shared with the respective site 
investigators .
Table 10summarizes the approximate blood volumes collected b y stud y visit a nd sample 
types. 
  05DKLV
080V09
PRODUCT: MK-8228 96
PROTOCOL/AMENDMENT N O.:040-02
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table 10 Approximate Blood/Tissue Volumes Drawn/Collected by  Study  Visit and by  Sample Ty pes
Study Period Treat ment Period Follow -upCMV i or 
Early D/C a
Visit No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Post-transplant (TP) WeekSCR 14
(D1)16 18 20 22 24 26 28 30 32 34 36 38 40 44 48
Blood Parameter
Hematology 2 2 2 2 2 2 2 2 2 2 2
Chemistry 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5
Coagulation PT/INR 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5
Serum (β -hCG)
(WOCBP only)3.5
HIV, Hepatitis B and C screenb16
CMV DNA PCRc6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
QuantiFERON -CMV assay 3 3 3 3
CMV DNA sequence analysisd10
Expected Total (mL) 38.5 16 16 16 16 16 16 16 19 11.5 6 6 6 6 6 6 9 29
β-hCG = β -Hum an Chorionic Gonadotropin; CMV = cytomegalovirus; DNA = deoxyribonucleic acid; D = day ; FU = follow -up; HIV = human immunodeficiency virus ; HSCT 
= hematopoietic stem cell transplant; IV = intravenous ;LET = letermovir ; PCR = polymerase chain r eaction ; PET = pre -emptive therapy; SCR = screening ; TP = Transplant; 
WOCBP = woman of childbearing potential.
a. The visit will be aCMV Infection Visit for all participants who meet the endpoint of CS -CMVi (defined as the occurrence of CMV disease or the initiation of PET)
through Week 48 post-transplant.  The visit can also be an Early Discontinuation Visit for those participants who are prematurely disconti nued from the trial up to 
Week 48 post-transplant.  All procedures should be performed at this visit immediately prior to the initiation of treatment of CMV diseases or initiation of PET (ie, on the 
day anti -CMV therapy is initiated).  Most importantly, a plasma sample for CMV PCR testing at the central laboratory should be collect ed at this visit. 
b. If not documented within the previous 6 months .  If hepatitis C virus antibody is positive, RNA PCR results should be prov ided.
c. Protocol-specified CMV DNA testing will be performed by the central laboratory using the Roche COBAS ®AmpliPrep/COBAS TaqMan ®[CAP/ CTM] System.
d. To be performed only in participant s with clinically significant CMV infection; For participants with clinically significant CMV infection, asample for CMV DNA 
sequence analysis for LET resistance should be collected at the CMVi visit and a second, confirmatory sample should be collected at the next scheduled visit
following the CMVi visit 
  05DKLV
080V09
PRODUCT: MK-8228 97
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
NOTE: For purposes of AE definition, study  intervention (also referred to as 
Sponsor’s product) includes an y pharmaceutical product, biological product, vaccine, 
device, diagnostic agent, or protocol specified procedure whether investigation al 
(including placebo or active comparator product) or marketed, manufactured by, 
licensed b y, provided b y, or distributed by  the Sponsor for human use in this study .
Events meeting the AE definition
Any abnormal laboratory test results (hematology , clinic al chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator.
Exace rbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present befor e the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
For all reports of overdos e (whether accidental or intentional) with an associated AE, 
the AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported 
using the terminology  “accidental or intentional overdose without adverse effect.”
Any new cancer or progression of existing cancer. 
  05DKLV
080V09
PRODUCT: MK-8228 98
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Events NOT meeting the AE d efinition
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Surgery  planned prior to informed consent to treat a pre- existing condition that has 
not worsened.
Refe r to Section 8.4.7 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SA E even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/inca pacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions. 
  05DKLV
080V09
PRODUCT: MK-8228 99
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
In offspring of participant taking the produ ct regardless of time to diagnosis.
f.Other important medical events
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may  
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
Is a cancer
Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics reports) 
related to the event.
The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to the Sponsor in lieu of completion of the AE CRF page. 
  05DKLV
080V09
PRODUCT: MK-8228 100
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
There may  be instances when copies of medical records for certain cases are 
requested b y the Sponsor. I n this case, all participant identifiers, with the exception of 
the participant number, will be blinded on the copies of the medical record s before 
submission to the Sponsor.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity
An event is defined as “serious” when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort, 
and not interfering with every day activities (f or pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  used for rating the 
intensity  of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely  distressed or unable to do usual activities).
Assessment of c ausality
Did the Sponsor ’s product cause the AE?
The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified ph ysician. The inves tigator’s 
signed/dated initials on the source document or worksheet that supports the causalit y 
noted on the AE form, ensures that a medically qualified assessment of causality was 
done. This initialed document must be retained for the required regulatory time frame. 
The criteria below are intended as reference guidelines to assist the investigator in 
assessing the likelihood of a relationship between the test product and the AE based 
upon the available information.
The following components are to be used t o assess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE: 
  05DKLV
080V09
PRODUCT: MK-8228 101
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pill 
count, diary , etc.), expected pharmacologic effect, or measurement of drug/metabolite 
in bodily  specimen?
-Time Course: Didthe AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? I s the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not rea sonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency  
reduced?
-If yes, did the AE resolve or improve?
-If yes, this is a positive dechallenge.
-If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability ; (2) the AE resolved/improved despite continuation of the Sponsor ’s 
product; (3) the stud y is a single -dose drug stud y; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability , or (2) the study  is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVE D IN 
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class p harmacology  or toxicology? 
  05DKLV
080V09
PRODUCT: MK-8228 102
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
The assessment of relationship will be reported on the case report forms/worksheets 
by an investigator who is a qualified ph ysician according to his/her best clinical 
judgment, including consideration of the above elements.
Use t he following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponso r’s product relationship:
-There is evidence of exposure to the Sponsor ’s pro duct. The temporal sequence of 
the AE onset relative to the administration of the Sponsor ’s product is reasonable. 
The AE is more likel y explained by the Sponsor ’s product than by  another cause.
-No, there is not a re asonable possibility  of Sponsor’ s produc t relationship:
-Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable OR 
the AE is more likely  explained by  another cause than the Sponsor’s product. 
(Also entered for a participant with overdose without an associated AE.)
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the Sponsor. However, it is very 
important that the investigator alway s make an assessment of causality  for every  
event before the initial transmission of the SAE data to the Sponsor.
The investigator may change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment.
The causality  assessment is 1 of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor 
to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
New or updated information will be recorded in the CRF.
The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information. 
  05DKLV
080V09
PRODUCT: MK-8228 103
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.3.5 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic d ata 
collection t ool
The primary  mechanism for reporting to the Sponsor will be the electronic data 
collection (EDC) tool.
Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
Reference Section 8.4.1  for reporting time requirements.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the EDC tool will be taken off -line to 
prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the EDC tool has been taken off -line, then the 
site can report this information on a paper SAE form or by telephone (see next 
section).
Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
In rare circumstances and in the absence of facsimile equipment, notificati on by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts and instructions for SAE reporting and paper reporting procedures can be 
found in the Investigator Study  File Binder (or equivalent). 
  05DKLV
080V09
PRODUCT: MK-8228 104
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluat ing, Follow -up, and Reporting
Not applicable . 
  05DKLV
080V09
PRODUCT: MK-8228 105
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl ysterile.
Women in the following categories are not considered WOCBP:
Premenarchal
Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history  interview.
Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause .
A high follicle st imulating hormone (FSH) level in the postmenopausal range may  be 
used to confirm a postmenopausal state in women not using hormonal contraception 
or hormone replacement therap y (HRT) .  However, in the absence of 12 months of 
amenorrhea, confirmation with 2 FSH measurements in the postmenopausal range is 
required.
-Females on HRT and whose menopausal status is in doubt will be required to use 
1 of the nonhormonal highly  effective contraception methods if they  wish to 
continue their HRT during the stud y.  Othe rwise, they  must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
10.5.2 Contraception Requirements
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to start 
contrac eption when initiating sexual activity  and they  agree to use 1 of the contraception 
methods described in Table 11consistently  and correctl y during the protocol -define d time 
frame in Section 5.1. 
  05DKLV
080V09
PRODUCT: MK-8228 106
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Table 11 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Com bined (estrogen -and progestogen -containing) hormonal contraceptionb,c
○Oral
○Intravaginal
○Transdermal
○Injectable
●Progestogen -only hormonal contraceptionb,c
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb,c 
●Intrauterine hormone -releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the so le 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined a s refraining from heterosexual 
intercourse during the entire period of risk associated with the study medication . The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of t he participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants of 
clinical studies.
aTypical use failure rates are higher than perfect -use failure rates (ie, when used consistently and 
correctly).
bIf locally required, in accordance with Clinical Trial Facilitation Group guidelines [Heads of Medicines 
Agencies 2014] , acceptable hormonal contraceptives are limited to those which inhibit ovulation. 
  05DKLV
080V09
PRODUCT: MK-8228 107
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.5.3 Pregnancy Testing
WOCBP should only  be included after a negative highl y sensitive urine or serum pregnancy 
test.
Following initiation of study  medication ,additional pregnancy  testing will be performed at 
monthly  intervals during the treatme nt period, for participants who complete the treatment 
period, at the CMV disease/earl y discontinuation visit , and as required locally.
Pregnancy  testing will be performed whenever an expected menstrual cy cle is missed or 
when pregnancy  is otherwise suspec ted. 
  05DKLV
080V09
PRODUCT: MK-8228 108
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.6 Appendix 6: Country -specific Requirements
Not applicable . 
  05DKLV
080V09
PRODUCT: MK-8228 109
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.7 Appendix 7 Definition of CMV Disease in Hematopoietic Stem Cell Transplant 
(HSCT) Recipients
CMV Disease
TypeProbable Proven Notes
Pneumonia Signs and/or symptoms of
pneumonia
AND
Detection ofCMV by
viral isolation, rapid
culture ofBAL fluid, or
thequantitation ofCMV
DNA inBAL fluidSigns and/or symptoms of
pulmonary disease
AND
Detection ofCMV inlung
tissue byvirus isolation,
rapid culture,
histopathology,
immunohistochemistry, or
DNA hybridization
techniquesPCR maybetoo
sensitive, sodetection of
CMV byPCR alone is
insufficient forthe
diagnosis ofCMV
pneumonia.
Superinfection or
coinfection with other
pathogens mayoccur
andshould benoted
when present .
GIDisease Symptoms ofupper
and/or lower GIdisease
AND
Evidence ofCMV intissue
butwithout the
requirement for
macroscopic mucosal
lesionsSymptoms ofupper and/or
lowerGIdisease
AND
Macroscopic mucosal
lesions
AND
Detection ofCMV inGItissue
byhistopathology, virus
isolation, rapid culture,
immunohistochemistry, or
DNA hybridizationDetection ofCMV by
PCR alone is
insufficient forthe
diagnosis ofCMV GI
disease.
Hepatitis N/A Abnormal liver function tests
AND
CMV documented intissue by
histopathology,
immunohistochemistry, virus
isolation, rapid culture, or
DNA hybridization techniques
AND
Absence ofother
documented cause of
hepatitisDetection ofCMV by
PCR alone isinsufficient
asitmayrepresent
transient DNAemia.
Hence, PCR is
insufficient todiagnose
CMV hepatitis.
Documentation ofCMV
inliver biopsy specimen
(ie,byculture,
histopathology,
immunohistochemical
analysis orinsitu
hybridization) isneeded.
Coinfection with other
pathogens likeHCV
maybepresent without 
excluding thediagnosis
ofCMV hepatitis. 
  05DKLV
080V09
PRODUCT: MK-8228 110
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
CMV Disease
TypeProbable Proven Notes
Encephalitis/
ventriculitisCNS symptoms
AND
Abnormal imaging results
orevidence of
encephalitis on
electroencephalography
AND
Detection ofCMV inCSF
without visible
contamination ofbloodCNS symptoms
AND
Detection ofCMV inCNS
tissue byvirus isolation,
rapid culture,
immunohistochemistry, in
situhybridization, or
(preferably) quantitative
PCRN/A
Retinitis N/A Lesions typical ofCMV
retinitis confirmed byan
ophthalmologist.N/A
Nephritis N/A Detection ofCMV byvirus
isolation, rapid culture,
immunohistochemistry, orin
situhybridization inakidney
allograft biopsy specimen
obtained from apatient with
renal dysfunction
AND
Identification ofhistologic
features ofCMV infectionDetection ofCMV in
urine byPCR orculture
isinsufficient forthe
diagnosis ofCMV
nephritis.
Cystitis N/A Detection ofCMV byvirus
isolation, rapid culture,
immunohistochemistry, orin
situhybridization inabladder
biopsy specimen obtained
from apatient with cystitis
AND
Identification of
conventional histologic
features ofCMV infectionDetection ofCMV in
urine byPCR orculture
isinsufficient forthe
diagnosis ofCMV
cystitis.
Myocarditis N/A Detection ofCMV byvirus
isolation, rapid culture,
immunohistochemistry, orin
situhybridization inaheart
biopsy specimen obtained
from apatient with
myocarditis
AND
Identification of
conventional histologic
features ofCMV infectionN/A 
  05DKLV
080V09
PRODUCT: MK-8228 111
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
CMV Disease
TypeProbable Proven Notes
Pancreatitis N/A Detection ofCMV byvirus
isolation, rapid culture,
immunohistochemistry, orin
situhybridization ina
pancreatic biopsy specimen
obtained from apatient with
pancreatitis
AND
Identification of
conventional histologic
features ofCMV infectionN/A
ALT =alanine aminotransferase; AST =aspartate aminotransferase; BAL =bronchoalveolar lavage;
CMV =cytomegalovirus; CNS =central nervous system; CSF =cerebrospinal fluid; DNA =
deoxyribonucleic acid; GI=gastrointestinal; HCV =hepatitis Cvirus; N/A =not applicable; PCR =
polymerase chain reaction; ULN =upper limit ofnormal 
  05DKLV
080V09
PRODUCT: MK-8228 112
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.8 Appendix 8 Child -Pugh Classification for Severity of Liver Disease
Scoring by Anomaly
Signs or symptom 1 point 2 points 3 points 
Hepatic encephalopath y1absent Grade 1 or Grade 2 Grade 3 or Grade 4 
Ascites absent mild moderate 
Bilirubin (μmol/L ) < 2 mg/dL 2 –3 mg/dL > 3 mg/dL 
Albumin (g/dL) > 3.5 g/dL 2.8 – 3.5 g/dL < 2.8 g/dL
Prothrombin time (I NR) < 1.7 1.7 – 2.3 > 2.3 
1Hepatic encephalopathy grading: 
Grade 1:  Altered mood/confusion
Grade 2:  Inappropriate behavior, impending stupor, somnolence
Grade 3:  Markedly confused, stuporous but arousable
Grade 4:  Comatose/unresponsive
Child -Pugh Score Interpretation
5 –6 points Child -Pugh stage A (mild hepatic insufficiency )
7 –9 points Child -Pugh stage B (moderate hepatic insufficiency*)
≥10 points Child -Pugh stage C (severe hepatic insufficiency)
*If hypoalbuminemia is the only abnormality noted, the participant will need to have a score of ≥7 to qualify 
for moderate hepatic insufficiency for this study.
Note:  Central laboratory test results will be used to determine Child- Pugh score at the 
Screening Visit.  Thereafter, local laboratory test results will be used for Child-Pugh scoring. 
  05DKLV
080V09
PRODUCT: MK-8228 113
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
10.9 Appendix 9: Abb reviations
Abbreviation Expanded Term
ADL activities of daily living  
AE adverse event 
BDS blood drug screen
CAC Clinical Adjudication Committee
CMV cytomegalovirus
CNS central nervous system 
CRF Case Report Form 
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale 
CTCAE Common Terminology Criteria for Adverse Events
DEHP diethylhexyl phthalate
DILI drug-induced liver injury
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
eCTA exploratory Clinical Trial Application
EDC electronic data collection 
EMA European Medicines Agency
EOC Executive Oversight Committee 
FDAAA Food and Drug Administration Amendments Act
FSH Follicle stimulating hormone 
GCP Good Clinical Practice 
GVHD graft -versus -host disease
HRT hormone replacement therapy
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IND Investigational New Drug 
IRB Institutional Review Board 
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing system
MTD maximum tolerated dose 
NA Not Applicable
NDA New  Drug Application 
NOAEL no observed adverse effect level 
PCR polymerase chain reaction
PES polyethersulfone
PET preemptive therapy
PK pharmacokinetic
PT/INR prothrombin time / international normalized ratio
QP2 department of quantitative pharmacology and pharmacometrics
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse event 
siDMC Standing Internal Data Monitoring Committee 
  05DKLV
080V09
PRODUCT: MK-8228 114
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
Abbreviation Expanded Term
SoA schedule of activities
SUSAR suspected unexpected serious adverse reaction
UDS urine drug screen
WOCBP woman/ women of childbearing potential  
  05DKLV
080V09
PRODUCT: MK-8228 115
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
11 REFERENCES
[Abate, D., et al 2013] Abate D, Saldan A, Mengoli C, Fiscon M, 
Silvestre C, Fallico L, et al. Comparison of 
cytomegalovirus (CMV) enzy me-linked 
immunosorbent spot and CMV quantiferon 
gamma interferon -releasing assay s in 
assessing risk of CMV infection in kidney  
transplant recipients. J Clin Microbiol. 2013 
Aug;51(8):2501 -7. Erratum in: J Clin 
Microbiol. 2014 Mar;52(3):1025.04MZPN
[Ariza -Heredia, E. J., et al 
2014]Ariza -Heredia EJ, Nesher L, Chemaly  RF. 
Cytomegalovirus diseases after hematopoietic 
stem cell transplantation: a mini -review. 
Cancer Lett. 2014 Jan 1;342(1):1 -8.04J8SD
[Becke, S., et al 2010] Becke S, Aue S, Thomas D, Schader S, 
Podlech J, Bopp T, et al. Optimized 
recombinant d ense bodies of human 
cytomegalovirus efficiently  prime virus 
specific l ymphocy tes and neutralizing 
antibodies without the addition of adjuvant. 
Vaccine. 2010 Aug 31;28(38):6191- 8.04N5S7
[Boeckh, M. 2011] Boeckh M. Complications, diagnosis, 
management, and prevention of CMV 
infections: Current and future. Am Soc 
Hematol 2011:305- 9.03RVM
Q
[Boeckh, M. and Geballe, A. 
P. 2011]Boeckh M, Geballe AP. Cy tomegalovirus: 
Pathogen, paradigm, and puzzle. J Clin I nvest 
2011;121(5):1673 -80.03RVMS
[Boeckh, M. and Nichols, W. 
G. 2004]Boeckh M, Nichols WG. The impact of 
cytomegalovirus serostatus of donor and 
recipient before hematopoietic stem cell 
transplantation in the era of antiviral 
prophy laxis and preemptive therap y. Blood 
2004;103:2003- 8.03RVM
R 
  05DKLV
080V09
PRODUCT: MK-8228 116
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
[Boeckh, M. , et al 2006] Boeckh M, Kim HW, Flowers MED, Mey ers 
JD, Bowden RA. L ong-term acy clovir for 
prevention of varicella zoster virus disease 
after allogeneic hematopoietic cell 
transplantation - a randomized double -blind 
placebo- controlled study . Blood. 2006 Ma r 
1;107(5):1800- 5.0500CK
[Boeckh, M., et al 2015] Boeckh M, Nichols WG, Chemaly  RF, 
Papanicolaou GA, Wingard JR, Xie H, et al. 
Valganciclovir for the  prevention of 
complications of late cy tomegalovirus 
infection after allogeneic hematopoietic cell 
trans plantation: a randomized trial. Ann I ntern 
Med. 2015 Jan  6;162(1):1 -10.04QQ3B
[Cantisan, S., et al 2013] Cantisan S, L ara R, Montejo M, Redel J, 
Rodriguez -Benot A, Gutierrez- Aroca J, et al. 
Pretransplant interferon- γ secretion by  CMV -
specific CD8+ T cel ls informs the risk of 
CMV replication after transplantation. Am J 
Transplant. 2013 Mar;13(3):738 -45.04MZPX
[Clopper, C. J. and Pearson, 
E. S. 1934]Clopper CJ, Pearson ES. The use of 
confidence or fiducial limits illustrated in the 
case of the binomial. Biometrika 
1934;26(4):404- 13.03Q0L W
[Craddock, C., et al 2001] Craddock C, Szy dlo RM, Dazzi F, Olavarria 
E, Cwy narski K, Yong A, et al. 
Cytomegalovirus seropositivity  adversel y 
influences outcome after T- depleted unrelated 
donor transplant in patients with chronic 
myeloid leukaemia: The case for tailored 
graft -versus- host disease prophy laxis. Br J 
Haematol 2001;112:228- 36.03RVN2
[Erard, V, Guthrie, K. A. 
2015]Erard V, Guthrie KA, Seo S, Smith J, Huang 
M, Chien J, et al. Reduced Mortality  of 
Cytomegal ovirus Pneumonia After 
Hematopoietic Cell Transplantation Due to 
Antiviral Therap y and Changes in 
Transplantation Practices. Clin I nfect Dis. 
2015 Jul 1;61(1):31 -9.04QQ3F 
  05DKLV
080V09
PRODUCT: MK-8228 117
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
[Fernandez -Ruiz, M., et al 
2014]Fernandez -Ruiz M, Kumar D, Humar A. 
Clinical immun e-monitoring strategies for 
predicting infection risk in solid organ 
transplantation. Clin Transl I mmunology . 
2014 Feb 28;3(2):e12.04MZPP
[Goldner, T., et al 2011] Goldner T, Hewlett G, Ettischer N, 
Ruebsamen -Schaeff H, Zimmerman H, 
Lischka P. The novel anticy tomegalovirus 
compound AIC246 (letermovir) inhibits 
human cy tomegalovirus replication through a 
specific antiviral mechanism that involves the 
viral terminase. J Virol 2011;85(20):10884 -
93.03RRNT
[Heads of Medicines 
Agencies 2014]Heads of Medicine s Agencies. Clinical Trial 
Facilitation Group - Recommendations related 
to contraception and pregnancy  testing in 
clinical trials [I nternet]. German y: HMA; 
2014. Available from: 
http://www.hma.eu/fileadmin/dateien/Human_
Medicines/01-
About_HMA/Working_Group s/CTFG/2014_0
9_HMA_CTFG_Contraception.pdf.04RP5D
[Huang, Y. T., et al 2016] Huang YT, Neofy tos D, Foldi J, Kim SJ, 
Maloy  M, Chung D, et al. Cy tomegalovirus 
Infection after CD34(+) -Selected 
Hematopoietic Cell Transplantation. Biol 
Blood Marrow Transplant. 2016 
Aug;22(8):1480 -1486.04S3JD
[Humar, A., et al 2010] Humar A, Lebranchu Y, Vincenti F, 
Blumberg EA, Punch JD, L imay e AP, et al. 
The efficacy  and safet y of 200 day s 
valganciclovir cy tomegalovirus prophy laxis in 
high-risk kidney  transplant recipients. Am J 
Transplant 2010;10:1228 -37.03RTL D
[Koch, G. G., et al 1990] Koch GG, Carr GJ, Amara IA, Stokes ME, 
Uryniak TJ. Statistical methodology  in the 
pharmaceutical sciences. Berry  DA. editor. 
New York: Marcel Dekker, Inc.; c1990. 
Chapter 13, Categorical da ta anal ysis; p. 389 -
473.04YBDZ 
  05DKLV
080V09
PRODUCT: MK-8228 118
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
[Larsson, K., et al 2004] Larsson K, Aschan J, Remberger M, Ringdén 
O, Winiarski J, L jungman P. Reduced risk for 
extensive chronic graft -versus- host disease in 
patients receiving transplants with human 
leukocy te antigen -identical sibling donors 
given pol ymerase chain reaction -based 
preemptive therap y against cytomegalovirus. 
Transplantation 2004;77(4):526- 31.03RVNB
[Lischka, P., et al 2010] Lischka P, Hewlett G, Wunberg T, 
Baumeister J, Paulsen D, Goldner T, et al. In 
vitro and in vivo activities of the novel 
anticy tomegalovirus compound AI C246. 
Antimicrob Agents Chemother. 2010 
Mar;54(3):1290 -703RRNQ
[Ljungman, P., et al 2002] Ljungman P, Griffiths P, Pay a C. Definitions 
of cy tomegalovirus infection and disease in 
transp lant recipients. Clin I nfect Dis 
2002;34:1094- 7.03RT9X
[Manuel, O., et al 2013] Manuel O, Husain S, Kumar D, Zay as C, 
Mawhorter S, Levi ME, et al. Assessment of 
cytomegalovirus -specific cell -mediated 
immunity  for the prediction of 
cytomegalovirus disease in high- risk solid-
organ transplant recipients: a multicenter 
cohort study . Clin Infect Dis 2013;56(6):817 -
24.03VTR9
[Martin, P. J. 2008] Martin PJ. Study  design and endpoints in 
graft -versus- host disease. Best Pract Res Clin 
Haematol. 2008;21(2):357- 72.04YQDT
[Martino, R., et al 2001] Martino R, Rovira M, Carreras E, Solano C, 
Sierra J, De La Rubia J, et al. Severe 
infections after allogeneic peripheral blood 
stem cell transplantation: a matched -pair 
comparison of unmanipulated and CD34+ 
cell-selected transplantation. Haematologica 
2001;86:1075- 86.03RVN7
[Marty , F. M. and Boeckh, 
M. 2011]Marty  FM, Boeckh M. Maribavir and human 
cytomegalovirus -what happened in the clinical 
trials and wh y might the drug have failed? 
Curr Opin Vir 2011;1:555 -62.03RVNC 
  05DKLV
080V09
PRODUCT: MK-8228 119
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
[Marty , F. M., et al 2017] Marty  FM, Ljungman P, Chemaly  RF, 
Maertens J, Dadwal SS, Duarte RF, et al. 
Letermovir proph ylaxis for cy tomegalovirus 
in hematopoietic -cell transplantation. N Engl J 
Med. 2017 Dec 21;377(25):2433 -44.04XH3T
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
analysis of two rates. Stat Med 1985;4:213 -26.03RVNK
[Miller, W., et al 1986] Miller W, Fly nn P, McCullough J, Balfour Jr. 
HH, Goldman A, Haake R, et al. 
Cytomegalovirus infection after bone marrow 
transplantation: An association with acute 
graft -v-host disease. Blood 1986;67(4):1162 -
7.03RVN6
[Özdemir, E., et al 2007] Ozdemir E, Saliba RM, Champlin RE, Couriel 
DR, Giralt SA, de Lima M. Risk factors 
associated with late cy tomegalovirus 
reactivation after allogeneic stem cell 
transplantation for hematological 
malignancies. Bone Marrow Transpl 
2007;40:125- 36.03RTB5
[Reusser, P., et al 1991] Reusser P, Riddell SR, Mey ers JD, Greenberg 
PD. Cy totoxic T -lymphocy te response to 
cytomegalovirus after human allogeneic bone 
marrow transplantation: pattern of recovery  
and correlation with cy tomegalovirus 
infection and disease. Blood. 1991 Sep 
1;78(5):1373 -80.052DPL
[Söderberg, C., et al 1993] Söderberg C, Larsson S, Bergstedt -Lindqvist 
S, Möller E. Definition of a subset of human 
peripheral blood mononuclear cells that are 
permissive to human cy tomegalovirus 
infection. J Virol 1993;67(6):3166 -75.03RVN8
[Teira, P., et al 2016] Teira P, Battiwalla M, Ramanathan M, Barrett 
AJ, Ahn KW, Chen M, et al. Earl y 
cytomegalovirus reactivation remains 
associated with increased transplant related 
mortality  in the current era: a CIBMTR 
analysis. Blood. 2016 Feb 16. pii: blood -2015-
11-679639. [Epub ahead of print].04CSVQ 
  05DKLV
080V09
PRODUCT: MK-8228 120
PROTOCOL/AMENDMENT N O.:040-02 
MK-8228 -040-02FINAL PROTOCOL 10-JAN-2020
[Zaia, J. A., et al 1997] Zaia JA, Gallez -Hawkins GM, Tegtmeier BR, 
ter Veer A, Li X, Niland JC, et al. L ate 
cytomegalovirus disease in marrow 
transplantation is predicted by  virus load in 
plasma. J I nfect Dis. 1997 Sep;176:782 -5.050278 
  05DKLV
080V09